MeSH term
Frequency | Condition_Probility | Acute Disease | 51 | 2.0 |
Adult | 631 | 1.0 |
Comparative Study | 220 | 0.0 |
Humans | 2005 | 0.0 |
Aged | 256 | 0.0 |
Risk | 5 | 0.0 |
Time Factors | 74 | 0.0 |
Female | 800 | 0.0 |
HLA Antigens/analysis | 6 | 2.0 |
Hepatitis B virus/immunology | 2 | 11.0 |
India | 13 | 4.0 |
Male | 759 | 0.0 |
Phenotype | 68 | 0.0 |
English Abstract | 151 | 1.0 |
Autoantibodies/analysis | 17 | 9.0 |
Complement 3/analysis | 221 | 69.0 |
Enzyme-Linked Immunosorbent Assay | 69 | 1.0 |
False Negative Reactions | 2 | 1.0 |
Fluorescent Antibody Technique, Direct | 5 | 4.0 |
Fluorescent Antibody Technique, Indirect | 6 | 0.0 |
Immunoglobulin G/*analysis | 13 | 17.0 |
Research Support, Non-U.S. Gov't | 884 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 71 | 0.0 |
Skin/immunology | 9 | 9.0 |
Animals | 390 | 0.0 |
*Apoptosis | 2 | 0.0 |
Cattle | 16 | 0.0 |
Cells, Cultured | 87 | 0.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Models, Biological | 11 | 0.0 |
Mutation | 16 | 0.0 |
Oxidation-Reduction | 9 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 457 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 13 | 1.0 |
Binding Sites | 40 | 0.0 |
Blotting, Western | 22 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Middle Aged | 447 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Transcription Factor, Sp1/*physiology | 2 | 2.0 |
Transfection | 12 | 0.0 |
Apoptosis | 3 | 0.0 |
Base Sequence | 66 | 0.0 |
DNA Primers | 6 | 0.0 |
Immunohistochemistry | 42 | 0.0 |
Mice | 127 | 0.0 |
Mice, Transgenic | 5 | 0.0 |
Antibody Formation/drug effects | 3 | 6.0 |
Asthma/drug therapy/*immunology | 2 | 25.0 |
Immunity, Cellular/drug effects | 3 | 5.0 |
Leukocyte Count | 28 | 1.0 |
Lymphocyte Activation | 24 | 0.0 |
Glucocorticoids/therapeutic use | 5 | 7.0 |
Immunosuppressive Agents/therapeutic use | 11 | 5.0 |
Kidney/pathology/physiopathology | 2 | 33.0 |
Kidney Glomerulus/pathology | 11 | 23.0 |
Microscopy, Electron | 38 | 1.0 |
Prednisolone/therapeutic use | 9 | 10.0 |
Gene Expression Regulation | 4 | 0.0 |
Swine | 27 | 1.0 |
Adsorption | 13 | 8.0 |
Complement 3/*metabolism | 111 | 69.0 |
Complement 3 Convertase/*metabolism | 3 | 17.0 |
*Complement Pathway, Alternative | 53 | 49.0 |
Fibrinogen/physiology | 4 | 26.0 |
Polystyrenes | 2 | 8.0 |
Aged, 80 and over | 63 | 0.0 |
Complement 3 Convertase/blood | 4 | 57.0 |
Complement Activation/*physiology | 11 | 45.0 |
Complement Pathway, Alternative/*physiology | 7 | 70.0 |
Complement Pathway, Classical/*physiology | 4 | 36.0 |
Prognosis | 36 | 0.0 |
Sensitivity and Specificity | 19 | 0.0 |
Treatment Outcome | 19 | 0.0 |
Blood Proteins/metabolism | 5 | 2.0 |
Chylomicrons/blood | 2 | 5.0 |
*Complement 3a/*analogs & derivatives | 6 | 30.0 |
Dietary Fats/metabolism | 2 | 6.0 |
Triglycerides/blood | 5 | 0.0 |
Cell Survival | 6 | 0.0 |
Cobra Venoms/pharmacology | 7 | 50.0 |
Complement 3/metabolism | 118 | 46.0 |
*Complement Activation | 190 | 47.0 |
Complement Membrane Attack Complex/physiology | 2 | 28.0 |
Complement Pathway, Classical | 48 | 41.0 |
Kinetics | 86 | 1.0 |
Mice, Inbred C57BL | 22 | 0.0 |
Mice, Knockout | 9 | 0.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
Receptors, Complement/*physiology | 7 | 12.0 |
Complement/drug effects | 2 | 50.0 |
Electrophysiology | 3 | 0.0 |
Hydrogen-Ion Concentration | 12 | 0.0 |
Kidney Tubules, Proximal/cytology/*physiology | 2 | 66.0 |
Urea/pharmacology | 2 | 5.0 |
Questionnaires | 2 | 0.0 |
Taiwan | 2 | 1.0 |
Adolescent | 286 | 1.0 |
Biopsy | 42 | 2.0 |
Complement 1q/*analysis | 3 | 75.0 |
Cyclophosphamide/therapeutic use | 5 | 5.0 |
Disease Progression | 15 | 0.0 |
Drug Therapy, Combination | 10 | 0.0 |
Kidney/*pathology | 9 | 16.0 |
Blood Transfusion | 4 | 2.0 |
Complement 1 Inactivators/*pharmacology | 3 | 60.0 |
In Vitro | 88 | 1.0 |
Solubility | 29 | 2.0 |
Swine/*immunology | 2 | 6.0 |
Transplantation, Heterologous | 6 | 0.0 |
B-Lymphocytes/*immunology | 8 | 0.0 |
Complement 3d/metabolism | 4 | 18.0 |
Complement 9/metabolism | 7 | 21.0 |
Complement Membrane Attack Complex/*biosynthesis | 2 | 28.0 |
Complement Pathway, Alternative/*immunology | 6 | 37.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Apoptosis/*immunology | 2 | 1.0 |
Complement 3/*immunology | 45 | 69.0 |
Complement 9/*immunology | 4 | 25.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Flow Cytometry | 24 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Cell Line | 60 | 0.0 |
Complement 3/*biosynthesis | 34 | 79.0 |
HIV Infections/immunology/virology | 2 | 7.0 |
HIV-1/*immunology | 12 | 2.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Up-Regulation | 7 | 0.0 |
Child | 230 | 1.0 |
Complement 3/metabolism/pharmacology | 2 | 100.0 |
Growth Inhibitors/pharmacology | 2 | 1.0 |
Heat | 27 | 5.0 |
Immunoglobulin M/immunology | 18 | 13.0 |
Lymphocyte Activation/immunology | 4 | 0.0 |
Phosphorylation | 10 | 0.0 |
Protein Binding/immunology | 8 | 4.0 |
Tyrosine/metabolism | 4 | 0.0 |
Biological Markers | 11 | 0.0 |
Complement 4/analysis/*immunology | 2 | 66.0 |
Complement Activation | 98 | 33.0 |
Follow-Up Studies | 34 | 0.0 |
Lymphocyte Activation/drug effects | 4 | 0.0 |
Signal Transduction/immunology | 2 | 0.0 |
Tumor Cells, Cultured | 23 | 0.0 |
Kidney/chemistry | 2 | 4.0 |
Rats | 65 | 0.0 |
Recurrence | 27 | 2.0 |
Laterality/*physiology | 3 | 10.0 |
Motor Cortex/*physiology | 3 | 15.0 |
Movement/*physiology | 5 | 13.0 |
Psychomotor Performance/physiology | 3 | 6.0 |
Complement 3c/*metabolism | 4 | 80.0 |
Double-Blind Method | 7 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 5 | 0.0 |
Risk Factors | 19 | 0.0 |
*Complement Pathway, Classical | 33 | 37.0 |
Cytotoxicity, Immunologic | 14 | 1.0 |
Leishmania/*immunology | 2 | 50.0 |
Phagocytosis | 37 | 9.0 |
Protein Binding | 50 | 0.0 |
Complement/analysis/*metabolism | 3 | 100.0 |
Graft Rejection | 4 | 2.0 |
Kidney Transplantation/*immunology | 4 | 1.0 |
Transplantation, Homologous | 9 | 1.0 |
Blood Proteins/*analysis | 14 | 9.0 |
Body Mass Index | 4 | 0.0 |
Fasting/*blood | 2 | 12.0 |
Lipids/blood | 5 | 0.0 |
Osmolar Concentration | 9 | 1.0 |
Antibody Specificity | 28 | 2.0 |
Case-Control Studies | 20 | 0.0 |
Complement 1q/*immunology | 4 | 44.0 |
Complement 4/*immunology | 4 | 21.0 |
Electrophoresis, Agar Gel | 11 | 2.0 |
Enzyme-Linked Immunosorbent Assay/methods | 4 | 1.0 |
Immunoenzyme Techniques | 25 | 0.0 |
Complement 3/*deficiency/*genetics | 4 | 100.0 |
Cysteine/metabolism | 2 | 2.0 |
Glycine/metabolism | 3 | 13.0 |
Homozygote | 14 | 0.0 |
Molecular Sequence Data | 108 | 0.0 |
*Mutation | 4 | 0.0 |
RNA, Messenger/analysis | 13 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Cell Separation | 3 | 0.0 |
Punctures | 2 | 22.0 |
Age of Onset | 6 | 0.0 |
Alleles | 37 | 0.0 |
Complement 3/*genetics | 51 | 86.0 |
Complement 4a/*genetics | 4 | 11.0 |
Complement 4b/*genetics | 3 | 8.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 8 | 0.0 |
HLA-B Antigens/*genetics | 2 | 0.0 |
Blood Proteins/*metabolism | 9 | 4.0 |
Electrophoresis, Gel, Two-Dimensional | 9 | 2.0 |
Immunoglobulin G/metabolism | 27 | 15.0 |
Materials Testing | 4 | 5.0 |
Serum Albumin/metabolism | 5 | 3.0 |
Surface Properties | 10 | 5.0 |
Vitronectin/metabolism | 2 | 11.0 |
CD4-CD8 Ratio | 2 | 0.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
Immunoglobulin G/blood | 13 | 4.0 |
Gene Frequency | 42 | 0.0 |
*Genetic Markers | 6 | 1.0 |
*Heterozygote | 2 | 0.0 |
Emotions/*physiology | 3 | 21.0 |
Microbial Sensitivity Tests | 2 | 0.0 |
Structure-Activity Relationship | 28 | 0.0 |
Complement 3a/*metabolism | 2 | 50.0 |
In Situ Hybridization | 11 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Biological Markers/blood | 7 | 0.0 |
Complement/*immunology/*metabolism | 2 | 66.0 |
Complement 3/immunology/metabolism | 2 | 33.0 |
Complement 4/immunology/metabolism | 2 | 50.0 |
Lupus Erythematosus, Systemic/diagnosis/*immunology | 4 | 50.0 |
Prospective Studies | 51 | 1.0 |
Retrospective Studies | 18 | 0.0 |
Severity of Illness Index | 17 | 1.0 |
Absorption | 3 | 2.0 |
Complement 3b/*immunology/metabolism | 2 | 33.0 |
Egtazic Acid/pharmacology | 15 | 14.0 |
Hemolysis/drug effects/immunology | 2 | 66.0 |
Microspheres | 8 | 4.0 |
Peptide Fragments/metabolism | 7 | 1.0 |
Rabbits | 78 | 2.0 |
Sepharose | 10 | 17.0 |
Glycoproteins/*immunology | 2 | 2.0 |
Complement 4/*metabolism | 15 | 34.0 |
Kidney/physiopathology | 4 | 6.0 |
Analysis of Variance | 12 | 0.0 |
Autoantibodies/*analysis | 17 | 7.0 |
Biological Markers/analysis | 3 | 0.0 |
Cohort Studies | 9 | 0.0 |
Cytokines/*analysis | 2 | 2.0 |
Lupus Erythematosus, Systemic/blood/*diagnosis | 2 | 66.0 |
Probability | 5 | 0.0 |
Regression Analysis | 11 | 0.0 |
Administration, Oral | 4 | 0.0 |
Cross-Over Studies | 2 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Cell Membrane/immunology | 9 | 3.0 |
Collectins | 7 | 8.0 |
Complement 3b/immunology | 10 | 29.0 |
Disease Models, Animal | 12 | 0.0 |
Complement 3/*analysis | 82 | 83.0 |
Electrochemistry | 2 | 2.0 |
Immunoassay/*methods | 4 | 5.0 |
Carrier Proteins/*blood | 2 | 0.0 |
Complement/*analysis | 95 | 54.0 |
Glomerulonephritis/complications/*immunology/pathology | 2 | 66.0 |
Kidney/immunology/pathology | 4 | 33.0 |
Precipitation | 14 | 9.0 |
Capsules | 2 | 4.0 |
Chemistry, Physical | 7 | 5.0 |
Macrophages/metabolism | 2 | 0.0 |
Microscopy, Electron, Scanning | 6 | 2.0 |
Complement 1q/immunology | 3 | 20.0 |
Complement 4/immunology | 14 | 35.0 |
Complement Activation/*immunology | 18 | 35.0 |
Immunoglobulin G/immunology | 22 | 6.0 |
Creatinine/blood | 10 | 3.0 |
Cyclophosphamide/administration & dosage/*therapeutic use | 2 | 22.0 |
Kidney/pathology | 18 | 12.0 |
Kidney Failure, Chronic/etiology | 5 | 18.0 |
Prednisone/therapeutic use | 8 | 7.0 |
Cell Line, Transformed | 2 | 0.0 |
Recombinant Proteins/genetics/immunology | 2 | 5.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Dose-Response Relationship, Drug | 25 | 0.0 |
Isomerism | 2 | 0.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Stereoisomerism | 4 | 1.0 |
Steroids/*pharmacology | 2 | 10.0 |
Xenopus laevis | 3 | 0.0 |
Antigen-Antibody Complex/*metabolism | 19 | 26.0 |
Glomerulonephritis/*etiology | 5 | 83.0 |
Antibodies, Monoclonal | 20 | 0.0 |
Complement 4/metabolism | 45 | 45.0 |
Immunoglobulin A/*metabolism | 3 | 10.0 |
Lectins/metabolism | 2 | 2.0 |
Autoimmunity | 3 | 2.0 |
Complement 1 Inactivators/*deficiency | 2 | 28.0 |
Syndrome | 8 | 0.0 |
Amino Acid Sequence | 82 | 0.0 |
Complement/genetics | 3 | 11.0 |
Complement 4/*genetics | 8 | 5.0 |
*Major Histocompatibility Complex | 2 | 0.0 |
Phylogeny | 11 | 0.0 |
Sequence Homology, Amino Acid | 17 | 0.0 |
Terminology | 2 | 1.0 |
Variation (Genetics) | 10 | 0.0 |
Complement Activation/*drug effects | 40 | 43.0 |
Complement Inactivators/analysis | 2 | 14.0 |
Immunoglobulin G/pharmacology | 2 | 3.0 |
*Membranes, Artificial | 5 | 5.0 |
*Renal Dialysis | 5 | 1.0 |
Reproducibility of Results | 10 | 0.0 |
Antigen-Antibody Complex/*physiology | 3 | 30.0 |
Arthritis, Rheumatoid/immunology | 18 | 18.0 |
Complement Pathway, Alternative | 60 | 51.0 |
Gamma-Globulins/pharmacology | 2 | 40.0 |
Lupus Erythematosus, Systemic/immunology | 25 | 22.0 |
Statistics, Nonparametric | 9 | 0.0 |
Stimulation, Chemical | 4 | 0.0 |
Child, Preschool | 114 | 1.0 |
Complement 3 Nephritic Factor/analysis | 6 | 85.0 |
Longitudinal Studies | 11 | 1.0 |
Survival Analysis | 3 | 0.0 |
ABO Blood-Group System/immunology | 4 | 16.0 |
Antithrombin III/analysis | 2 | 1.0 |
Blood Cell Count | 8 | 3.0 |
Complement 3a/analysis | 6 | 35.0 |
Complement Membrane Attack Complex/analysis | 4 | 25.0 |
Graft Rejection/*immunology | 2 | 2.0 |
*Models, Immunological | 2 | 4.0 |
Perfusion | 5 | 2.0 |
Transplantation, Heterologous/*immunology | 5 | 8.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Postoperative Complications | 2 | 1.0 |
Survival Rate | 8 | 0.0 |
Cell Migration Inhibition | 4 | 3.0 |
Complement 3/biosynthesis/*deficiency/*genetics | 2 | 100.0 |
Fibroblasts/metabolism | 8 | 0.0 |
Hemolysis | 72 | 22.0 |
Pedigree | 42 | 0.0 |
Complement 3/*antagonists & inhibitors | 2 | 66.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
*Polymorphism, Genetic | 45 | 0.0 |
Smoking/adverse effects | 3 | 1.0 |
3T3 Cells | 2 | 0.0 |
Complement 3/genetics/*metabolism | 3 | 50.0 |
Cycloheximide/pharmacology | 12 | 1.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 8 | 0.0 |
Complement 5/metabolism | 14 | 32.0 |
Family Health | 4 | 0.0 |
Complement 3b/immunology/metabolism | 6 | 50.0 |
Complement 3c/immunology/metabolism | 2 | 100.0 |
Complement 4b/immunology/metabolism | 2 | 100.0 |
Complement Membrane Attack Complex/*urine | 2 | 66.0 |
Prednisolone/administration & dosage | 3 | 4.0 |
Complement 2/immunology | 3 | 27.0 |
Complement 3/immunology | 34 | 48.0 |
Complement Factor B/immunology | 6 | 66.0 |
Escherichia coli/immunology | 10 | 14.0 |
Heating | 2 | 9.0 |
Leukocytes/immunology | 6 | 4.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 7 | 18.0 |
Phagocytosis/*immunology | 2 | 3.0 |
Staphylococcus aureus/immunology | 7 | 6.0 |
Streptococcus pneumoniae/immunology | 4 | 19.0 |
Evolution, Molecular | 2 | 0.0 |
Gene Expression Regulation/drug effects | 5 | 0.0 |
Antibodies, Antinuclear/blood | 7 | 14.0 |
Lupus Erythematosus, Systemic/blood/*drug therapy | 2 | 66.0 |
Proteinuria/urine | 3 | 18.0 |
Apolipoproteins C/genetics | 3 | 8.0 |
Apolipoproteins E/genetics | 3 | 0.0 |
Cholesterol/blood | 6 | 0.0 |
Lipids/*blood | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 4 | 0.0 |
Polymerase Chain Reaction | 32 | 0.0 |
Polymorphism, Genetic | 30 | 0.0 |
Sex Factors | 13 | 0.0 |
Corticotropin/blood | 2 | 1.0 |
Cross-Sectional Studies | 5 | 0.0 |
C-Reactive Protein/metabolism | 5 | 1.0 |
Fibrinogen/metabolism | 7 | 3.0 |
Antigen-Antibody Complex/*immunology | 20 | 24.0 |
Casein Kinases | 2 | 4.0 |
Complement 3/immunology/*metabolism | 11 | 78.0 |
Complement Factor B/metabolism | 28 | 68.0 |
Complement Factor H/metabolism | 6 | 46.0 |
Erythrocytes/immunology/metabolism | 3 | 25.0 |
Immunoglobulin G/immunology/metabolism | 2 | 12.0 |
Opsonins/*immunology | 6 | 33.0 |
Protein Kinases/*metabolism | 3 | 0.0 |
Receptors, Complement/*metabolism | 12 | 11.0 |
Complement 3/analysis/*biosynthesis | 3 | 100.0 |
Complement Activation/physiology | 3 | 15.0 |
Kidney Glomerulus/*immunology/pathology | 4 | 40.0 |
Lipoprotein(a)/*blood | 2 | 2.0 |
DNA Primers/genetics | 8 | 0.0 |
Mice, Inbred BALB C | 20 | 0.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Interleukin-6/pharmacology | 4 | 1.0 |
Lipopolysaccharides/pharmacology | 11 | 1.0 |
Liver Neoplasms | 4 | 1.0 |
Binding, Competitive | 18 | 0.0 |
Complement/*metabolism | 64 | 37.0 |
Complement 3a/metabolism | 3 | 18.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Ligands | 9 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Neutrophils/metabolism | 6 | 4.0 |
Umbilical Veins/cytology | 3 | 1.0 |
African Continental Ancestry Group/*genetics | 3 | 1.0 |
*Alleles | 10 | 0.0 |
Haplotypes | 3 | 0.0 |
Pan troglodytes | 3 | 2.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Brain/*physiopathology | 4 | 9.0 |
*Electroencephalography | 18 | 16.0 |
Biomechanics | 2 | 1.0 |
Antibodies/immunology | 6 | 1.0 |
Complement 2/*biosynthesis | 5 | 20.0 |
Complement/*deficiency | 11 | 23.0 |
Glomerular Mesangium/chemistry/pathology | 2 | 66.0 |
Hematuria/etiology | 4 | 33.0 |
Immunoglobulin A/analysis | 47 | 28.0 |
Proteinuria/etiology | 4 | 13.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Electroencephalography | 12 | 4.0 |
Electromyography | 4 | 2.0 |
Frontal Lobe/*physiopathology | 2 | 33.0 |
Fourier Analysis | 4 | 7.0 |
Amino Acid Substitution | 3 | 0.0 |
Codon | 2 | 0.0 |
HIV-1/*genetics | 2 | 0.0 |
Models, Molecular | 8 | 0.0 |
Protein Conformation | 30 | 0.0 |
*Variation (Genetics) | 10 | 0.0 |
Antigen-Antibody Reactions | 9 | 2.0 |
Binding Sites, Antibody | 14 | 4.0 |
Epitopes/*immunology | 4 | 1.0 |
Immunoglobulin G/blood/immunology | 2 | 4.0 |
Neutralization Tests | 10 | 2.0 |
Peptide Fragments/immunology | 6 | 2.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Complement 3/*biosynthesis/genetics | 15 | 88.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Gene Expression | 14 | 0.0 |
Kidney Tubules, Proximal/*metabolism | 2 | 16.0 |
Japan | 4 | 0.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Age Factors | 24 | 0.0 |
Brain Mapping | 8 | 5.0 |
Cerebral Cortex/physiopathology | 2 | 8.0 |
Laterality/physiology | 7 | 13.0 |
Pain/*physiopathology | 2 | 6.0 |
Photic Stimulation/methods | 2 | 8.0 |
Psychomotor Performance/*physiology | 5 | 11.0 |
Reaction Time/physiology | 6 | 6.0 |
Brain/*physiology | 4 | 3.0 |
Electrooculography | 4 | 9.0 |
*Evoked Potentials, Auditory | 4 | 12.0 |
*Evoked Potentials, Motor | 2 | 50.0 |
Motor Cortex/physiology | 2 | 18.0 |
Muscle Contraction/*physiology | 3 | 7.0 |
Blood | 9 | 4.0 |
Complement Hemolytic Activity Assay | 13 | 26.0 |
Electrophoresis, Polyacrylamide Gel | 87 | 2.0 |
Immunoblotting | 22 | 0.0 |
Neuropsychological Tests | 3 | 1.0 |
Complement/analysis | 70 | 51.0 |
Pre-Eclampsia/*immunology | 2 | 14.0 |
Pregnancy | 46 | 0.0 |
Complement 3a/*analysis | 3 | 60.0 |
Infant | 56 | 0.0 |
Complement 1q/analysis | 11 | 64.0 |
Fibrin/analysis | 5 | 16.0 |
Fluorescent Antibody Technique | 116 | 4.0 |
Immunoglobulin M/analysis | 59 | 26.0 |
Inflammation | 2 | 0.0 |
Kidney/immunology/*pathology | 2 | 50.0 |
Kidney Glomerulus/immunology/pathology | 7 | 53.0 |
Microscopy, Fluorescence | 21 | 1.0 |
Predictive Value of Tests | 8 | 0.0 |
Cognition/*physiology | 4 | 5.0 |
*Firearms | 2 | 50.0 |
Temporal Lobe/*physiology | 2 | 33.0 |
Visual Perception/*physiology | 3 | 11.0 |
Crystallography, X-Ray | 3 | 0.0 |
*Magnetic Resonance Spectroscopy | 2 | 4.0 |
*Models, Molecular | 2 | 1.0 |
Sequence Alignment | 10 | 0.0 |
Temperature | 16 | 1.0 |
Thermodynamics | 5 | 1.0 |
ABO Blood-Group System/*immunology | 2 | 16.0 |
Graft Rejection/immunology | 2 | 3.0 |
Kidney/*immunology/pathology | 2 | 28.0 |
Papio | 3 | 1.0 |
Basement Membrane/pathology | 4 | 11.0 |
Kidney Glomerulus/blood supply/pathology | 2 | 50.0 |
Hematuria | 4 | 100.0 |
Remission, Spontaneous | 2 | 2.0 |
Adjuvants, Immunologic/*therapeutic use | 4 | 5.0 |
Phagocytes/immunology | 3 | 12.0 |
Binding, Competitive/immunology | 4 | 4.0 |
Complement 1 Inactivators/metabolism | 3 | 18.0 |
Complement Activation/immunology | 7 | 21.0 |
Dose-Response Relationship, Immunologic | 25 | 4.0 |
Hydrolysis | 9 | 1.0 |
Biotransformation | 2 | 0.0 |
Chemotaxis, Leukocyte/drug effects | 2 | 2.0 |
Complement/metabolism | 26 | 27.0 |
Immune System/*drug effects | 3 | 12.0 |
Immunoglobulins/blood | 4 | 4.0 |
Killer Cells, Natural/drug effects | 2 | 5.0 |
Neutrophils/drug effects | 3 | 5.0 |
Complement 3/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Complement 3 Convertase/antagonists & inhibitors | 2 | 25.0 |
Complement Inactivators/*pharmacology | 5 | 19.0 |
Hemolysis/drug effects | 11 | 18.0 |
Calibration | 2 | 1.0 |
Reference Values | 37 | 0.0 |
Complement Pathway, Alternative/*drug effects | 15 | 68.0 |
Complement Pathway, Classical/*drug effects | 4 | 23.0 |
Chemotaxis | 4 | 2.0 |
Complement 3b | 5 | 45.0 |
Complement Factor H/*metabolism | 2 | 12.0 |
Complement Pathway, Alternative/physiology | 2 | 40.0 |
Complement Pathway, Classical/physiology | 2 | 33.0 |
Erythrocytes | 5 | 10.0 |
Guinea Pigs | 53 | 6.0 |
Immunoelectrophoresis | 44 | 18.0 |
Complement/*genetics | 5 | 8.0 |
Endothelium, Vascular/*metabolism | 4 | 1.0 |
RNA, Messenger/genetics | 16 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Umbilical Veins | 3 | 0.0 |
Cell Cycle | 2 | 0.0 |
Cell Death | 2 | 0.0 |
Cell Division | 5 | 0.0 |
DNA/metabolism | 4 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Complement 3 Convertase/metabolism | 13 | 33.0 |
Dimerization | 2 | 0.0 |
Radioimmunoassay | 19 | 1.0 |
Sodium Chloride/pharmacology | 2 | 2.0 |
Neutrophils/pathology | 2 | 3.0 |
Lupus Erythematosus, Systemic/blood/*metabolism | 2 | 66.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Antibody Formation | 27 | 6.0 |
Antigens, CD/immunology | 2 | 0.0 |
*Helicobacter pylori | 3 | 2.0 |
Immunity, Cellular | 25 | 3.0 |
Immunoglobulins/analysis | 63 | 25.0 |
*Cardiopulmonary Bypass | 5 | 5.0 |
Erythrocytes/*immunology | 11 | 5.0 |
Creatinine/metabolism | 2 | 2.0 |
Kidney Glomerulus/metabolism | 2 | 10.0 |
*Streptococcal Infections | 2 | 66.0 |
Antibodies, Antinuclear/*blood | 3 | 25.0 |
DNA/*immunology | 9 | 23.0 |
Length of Stay | 3 | 3.0 |
Diagnosis, Differential | 26 | 1.0 |
Prevalence | 6 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Complement 2/biosynthesis/genetics | 2 | 40.0 |
Complement 3/biosynthesis/genetics | 2 | 66.0 |
Infant, Newborn | 38 | 0.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Drug Resistance | 4 | 0.0 |
ADP Ribose Transferases/pharmacology | 7 | 21.0 |
Amides/pharmacology | 2 | 3.0 |
Botulinum Toxins/pharmacology | 2 | 11.0 |
Interleukin-8/pharmacology | 2 | 4.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 5 | 1.0 |
Neutrophils/drug effects/*metabolism | 2 | 3.0 |
Pyridines/pharmacology | 2 | 0.0 |
rhoA GTP-Binding Protein/antagonists & inhibitors/*metabolism | 2 | 25.0 |
Interferon Type II/pharmacology | 9 | 1.0 |
*Photochemotherapy | 2 | 4.0 |
*Ultraviolet Rays | 2 | 0.0 |
*Kidney Transplantation | 15 | 3.0 |
Acute-Phase Proteins/analysis | 2 | 5.0 |
*Altitude | 2 | 3.0 |
Disease Susceptibility | 9 | 1.0 |
Lymphokines/*blood | 2 | 0.0 |
Chromosome Mapping | 9 | 0.0 |
Haptoglobins/*genetics | 2 | 5.0 |
Models, Theoretical | 2 | 1.0 |
*Phenotype | 4 | 1.0 |
Cryoglobulins/*analysis | 5 | 71.0 |
Italy/epidemiology | 4 | 1.0 |
Multivariate Analysis | 10 | 0.0 |
Complement Factor B/*biosynthesis/genetics | 2 | 40.0 |
Drug Synergism | 5 | 0.0 |
Fibroblasts/*immunology/metabolism | 2 | 40.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Skin/*immunology | 10 | 9.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
Electroencephalography/*drug effects | 4 | 19.0 |
Binding Sites/genetics | 2 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Antibodies, Antinuclear | 2 | 28.0 |
Immunoglobulin M/metabolism | 11 | 13.0 |
Nephrotic Syndrome/*etiology/pathology | 2 | 100.0 |
Immunoglobulin G/analysis | 84 | 21.0 |
Lung/immunology/pathology | 2 | 8.0 |
Lung Transplantation/*immunology | 2 | 22.0 |
Pulmonary Circulation | 4 | 15.0 |
Vascular Resistance | 2 | 3.0 |
Antigen-Antibody Complex/immunology | 8 | 13.0 |
Arthritis, Juvenile Rheumatoid/blood/*immunology | 4 | 57.0 |
Blood Sedimentation | 8 | 4.0 |
C-Reactive Protein/analysis | 14 | 2.0 |
*Complement 4b | 14 | 43.0 |
Complement 5/immunology | 3 | 17.0 |
Complement 4/analysis | 145 | 70.0 |
*Bone Development | 2 | 14.0 |
*Blood Transfusion | 2 | 1.0 |
Galactosides/immunology | 2 | 100.0 |
Immunosorbent Techniques | 5 | 1.0 |
Immunosuppression/methods | 2 | 6.0 |
Lung/drug effects/*pathology | 2 | 28.0 |
Antibodies/*analysis | 6 | 5.0 |
Antibodies, Antinuclear/analysis | 24 | 32.0 |
DNA/immunology | 14 | 30.0 |
Lupus Erythematosus, Systemic/*diagnosis | 3 | 50.0 |
Antibody Affinity | 6 | 3.0 |
Bone Marrow/immunology | 2 | 1.0 |
Cross Reactions | 14 | 1.0 |
Spleen/immunology | 4 | 2.0 |
Complement 3/chemistry/*metabolism | 5 | 100.0 |
Complement Factor B/*biosynthesis | 6 | 50.0 |
Monocytes/metabolism | 4 | 1.0 |
Protein Biosynthesis | 5 | 0.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Endocytosis | 2 | 0.0 |
alpha-Macroglobulins/*metabolism | 4 | 12.0 |
Biopsy, Needle | 4 | 0.0 |
Complement 3c/*analysis | 3 | 100.0 |
Kidney Transplantation | 6 | 4.0 |
Renal Dialysis | 8 | 2.0 |
Thrombocytopenia/*etiology | 2 | 12.0 |
Cercopithecus aethiops | 2 | 0.0 |
Rosette Formation | 26 | 8.0 |
Kidney Glomerulus/ultrastructure | 3 | 30.0 |
Serum Albumin/analysis | 9 | 4.0 |
Chemical Fractionation | 2 | 2.0 |
Zymosan/immunology | 3 | 50.0 |
Complement 2/*deficiency | 3 | 5.0 |
Drug Administration Schedule | 6 | 0.0 |
Evoked Potentials, Somatosensory/*physiology | 4 | 14.0 |
Hand/innervation/physiology | 2 | 66.0 |
Physical Stimulation | 2 | 4.0 |
*Vibration | 2 | 14.0 |
Antigen-Antibody Complex/*blood | 5 | 9.0 |
Blood Platelets/*immunology | 12 | 15.0 |
Hepatitis/complications | 2 | 22.0 |
Immunoglobulin G/*blood | 3 | 4.0 |
Lupus Erythematosus, Systemic/complications | 3 | 33.0 |
Injections, Intravenous | 8 | 1.0 |
Models, Chemical | 2 | 0.0 |
Autoantibodies/*blood | 7 | 2.0 |
Chronic Disease | 30 | 1.0 |
*Antigens, CD44 | 2 | 9.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Bacterial Adhesion | 4 | 6.0 |
Blood Bactericidal Activity | 16 | 16.0 |
Complement/physiology | 2 | 4.0 |
Virulence | 9 | 3.0 |
Complement/biosynthesis/*genetics | 2 | 50.0 |
Guanidines/pharmacology | 2 | 4.0 |
Culture Techniques | 6 | 1.0 |
Immunity/*physiology | 2 | 9.0 |
Tumor Necrosis Factor-alpha/*secretion | 2 | 2.0 |
Angiography/adverse effects | 2 | 66.0 |
Contrast Media/*adverse effects | 3 | 20.0 |
Blotting, Northern | 14 | 0.0 |
Cell Membrane/metabolism | 7 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Species Specificity | 29 | 1.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
Blood Platelets/metabolism | 4 | 2.0 |
Complement Activation/drug effects | 6 | 33.0 |
*Extracorporeal Circulation | 3 | 12.0 |
Monocytes/drug effects/*metabolism | 3 | 2.0 |
Abortion, Spontaneous/*immunology | 2 | 13.0 |
Antigen-Antibody Complex/blood | 6 | 19.0 |
Complement Factor B/analysis | 27 | 62.0 |
Immunoglobulin A/blood | 9 | 8.0 |
Immunoglobulin M/blood | 10 | 7.0 |
Lupus Erythematosus, Systemic/*immunology | 28 | 18.0 |
Rheumatoid Factor/blood | 4 | 10.0 |
Seroepidemiologic Studies | 3 | 2.0 |
Antigens/immunology | 2 | 1.0 |
Complement 1/immunology | 4 | 25.0 |
Complement 3b/metabolism | 30 | 29.0 |
Complement Pathway, Classical/*immunology | 3 | 50.0 |
Leukocytes/*immunology | 6 | 4.0 |
Platelet Activation/*immunology | 2 | 11.0 |
Prekallikrein/metabolism | 2 | 40.0 |
Complement 4/*analysis | 33 | 68.0 |
Infertility, Male/*immunology | 2 | 25.0 |
Semen/*immunology | 2 | 16.0 |
Spermatozoa/*immunology | 2 | 4.0 |
Attention/*physiology | 3 | 7.0 |
Electrodes | 3 | 6.0 |
Evoked Potentials, Visual/*physiology | 2 | 11.0 |
*Sex Characteristics | 3 | 2.0 |
Antibodies, Monoclonal/*immunology | 14 | 1.0 |
Immunoglobulins, Fc/immunology | 2 | 8.0 |
Receptors, Complement/*immunology | 5 | 7.0 |
Complement Pathway, Alternative/immunology | 5 | 38.0 |
Complement Pathway, Classical/immunology | 4 | 44.0 |
Glycerol/metabolism | 2 | 5.0 |
Trypsin/metabolism | 2 | 1.0 |
Rats, Wistar | 6 | 0.0 |
Complement 1 Inactivators/deficiency | 3 | 60.0 |
*Complement Inactivators | 9 | 11.0 |
*Glycoproteins | 4 | 0.0 |
*Disease Outbreaks | 4 | 6.0 |
Taiwan/epidemiology | 2 | 1.0 |
Genetic Markers/*genetics | 2 | 1.0 |
*Genetic Vectors | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Antigens, CD/*immunology | 2 | 0.0 |
Complement Inactivators/*immunology | 4 | 33.0 |
Dogs | 11 | 0.0 |
Complement 3/analysis/*genetics | 3 | 60.0 |
DNA/genetics | 5 | 0.0 |
Gene Deletion | 4 | 0.0 |
HLA Antigens/genetics | 2 | 0.0 |
Complement 3/*isolation & purification | 8 | 72.0 |
B-Lymphocytes/immunology | 9 | 1.0 |
Receptors, Complement/immunology | 7 | 21.0 |
Interleukin-6/blood | 5 | 1.0 |
Pancreatic Elastase/blood | 5 | 20.0 |
Antibodies, Monoclonal/blood | 2 | 15.0 |
Kidney Transplantation/immunology | 3 | 5.0 |
Postoperative Period | 5 | 1.0 |
Antigens, CD/analysis | 4 | 0.0 |
Fetus | 3 | 0.0 |
Macaca fascicularis | 3 | 1.0 |
Greece | 4 | 4.0 |
*Botulinum Toxins | 6 | 13.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
Enzyme Activation | 11 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
*Gene Deletion | 2 | 0.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Alzheimer Disease/*metabolism | 3 | 1.0 |
Brain/*metabolism | 4 | 0.0 |
RNA, Messenger/metabolism | 15 | 0.0 |
Evolution | 7 | 1.0 |
Genes, Structural | 4 | 0.0 |
United States | 5 | 0.0 |
Alcoholism/*complications | 2 | 10.0 |
Evoked Potentials/*physiology | 2 | 10.0 |
Pattern Recognition, Visual/physiology | 2 | 15.0 |
Reaction Time | 2 | 1.0 |
Caco-2 Cells | 2 | 0.0 |
Interleukin-1/*pharmacology | 8 | 1.0 |
Blood Pressure | 8 | 1.0 |
Clinical Trials | 7 | 0.0 |
Incidence | 2 | 0.0 |
Sex Characteristics | 5 | 0.0 |
Complement 4/*biosynthesis | 7 | 87.0 |
Heart Rate | 2 | 0.0 |
*Hemodynamic Processes | 2 | 4.0 |
Immunosuppressive Agents/*therapeutic use | 2 | 1.0 |
Methylprednisolone/therapeutic use | 3 | 6.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Depression, Chemical | 3 | 1.0 |
Glomerular Mesangium/immunology | 2 | 25.0 |
Phagocytosis/drug effects | 5 | 5.0 |
Cerebral Cortex/*physiology | 3 | 7.0 |
Contingent Negative Variation/*physiology | 4 | 57.0 |
Complement/*immunology | 20 | 14.0 |
Complement 9/immunology | 2 | 11.0 |
Autoantigens/immunology | 2 | 1.0 |
Autoimmune Diseases/immunology | 8 | 9.0 |
Chromatography, Affinity | 14 | 1.0 |
Epitopes/*analysis | 10 | 6.0 |
Anti-Inflammatory Agents/therapeutic use | 3 | 3.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Lupus Nephritis/blood/*drug therapy/pathology | 2 | 100.0 |
Proteinuria/drug therapy | 4 | 30.0 |
Liver/chemistry/immunology | 2 | 100.0 |
Oligonucleotide Probes | 3 | 0.0 |
Autoantibodies/blood | 3 | 1.0 |
Lupus Erythematosus, Systemic/*immunology/pathology | 2 | 28.0 |
*Graft Rejection | 7 | 7.0 |
Baculoviridae/genetics | 2 | 1.0 |
Fibrinogen/pharmacology | 2 | 13.0 |
Graft Rejection/prevention & control | 2 | 4.0 |
Hamsters | 4 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Protein Engineering | 2 | 2.0 |
Antibodies, Bacterial/blood | 2 | 2.0 |
Complement 3/*deficiency/immunology | 2 | 100.0 |
Neisseria meningitidis/*immunology | 2 | 11.0 |
Vaccination | 2 | 1.0 |
Immunoglobulins/*metabolism | 4 | 7.0 |
Arousal/*physiology | 3 | 10.0 |
Cerebral Cortex/physiology | 2 | 10.0 |
Theta Rhythm | 2 | 15.0 |
Lupus Erythematosus, Systemic/complications/*immunology | 3 | 30.0 |
Complement/*deficiency/genetics | 2 | 50.0 |
Complement 1q/deficiency | 2 | 66.0 |
Complement 3/deficiency | 9 | 52.0 |
Complement 4/deficiency | 10 | 41.0 |
Danazol/therapeutic use | 3 | 30.0 |
Stanozolol/therapeutic use | 2 | 100.0 |
Complement Factor I/metabolism | 6 | 66.0 |
Peptide Fragments | 3 | 4.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Liver/cytology | 2 | 3.0 |
Mice, Inbred DBA | 2 | 0.0 |
Mice, Nude | 3 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Blood Glucose/metabolism | 4 | 0.0 |
Carbon Isotopes | 4 | 7.0 |
Glutamine/metabolism | 2 | 8.0 |
Macromolecular Substances | 17 | 0.0 |
Candida albicans/*immunology | 4 | 20.0 |
Immunoglobulins, Fab/immunology | 7 | 6.0 |
Mannans/*immunology | 2 | 28.0 |
African Continental Ancestry Group | 2 | 0.0 |
South Africa | 3 | 2.0 |
Peptide Fragments/analysis | 19 | 8.0 |
Receptors, Complement/analysis | 9 | 16.0 |
Biocompatible Materials | 3 | 4.0 |
*Prostheses and Implants | 2 | 9.0 |
beta-Thromboglobulin/metabolism | 2 | 3.0 |
Kidney/metabolism | 4 | 1.0 |
Kidney Function Tests | 6 | 5.0 |
Peroxidase/metabolism | 2 | 1.0 |
*Receptors, Cell Surface | 2 | 0.0 |
Complement Membrane Attack Complex/*metabolism | 3 | 14.0 |
Neurons/*metabolism | 3 | 1.0 |
Phospholipase C/pharmacology | 2 | 5.0 |
Hypersensitivity/immunology | 3 | 7.0 |
Complement 3d/*metabolism | 2 | 18.0 |
Complement Factor B/*metabolism | 7 | 58.0 |
Hong Kong | 3 | 6.0 |
Blotting, Southern | 8 | 0.0 |
Cats | 3 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
*Biocompatible Materials | 2 | 5.0 |
Calcium/blood | 2 | 0.0 |
Culture Media | 8 | 1.0 |
Edetic Acid/pharmacology | 26 | 14.0 |
Complement 3/genetics | 13 | 36.0 |
*Gene Frequency | 11 | 2.0 |
Haptoglobins/genetics | 5 | 10.0 |
Lactoylglutathione Lyase/genetics | 3 | 6.0 |
Phosphoglucomutase/genetics | 3 | 6.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Russia | 2 | 2.0 |
Transferrin/genetics | 5 | 10.0 |
Liver Cirrhosis, Alcoholic/*immunology | 2 | 40.0 |
Pain Measurement | 2 | 2.0 |
Gene Expression/physiology | 2 | 0.0 |
Antibody Formation/immunology | 2 | 4.0 |
Cardiopulmonary Bypass | 3 | 6.0 |
Heart Defects, Congenital/surgery | 2 | 20.0 |
Immunity, Cellular/immunology | 3 | 5.0 |
Thromboxane B2/blood | 2 | 5.0 |
Tumor Necrosis Factor-alpha/analysis | 3 | 0.0 |
Liver Cirrhosis, Biliary/blood/*immunology | 3 | 42.0 |
Complement 2/metabolism | 8 | 29.0 |
DNA, Viral | 3 | 1.0 |
Interleukin-1/pharmacology | 10 | 1.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Conserved Sequence | 4 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptors, Complement 3d/*metabolism | 3 | 15.0 |
Neutrophils/immunology | 18 | 10.0 |
Complement 9/analysis | 10 | 38.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 3 | 2.0 |
Kidney Glomerulus/*ultrastructure | 4 | 80.0 |
Paraproteinemias/*complications | 2 | 33.0 |
Lupus Erythematosus, Systemic/*diagnosis/*immunology | 2 | 100.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Complement/*physiology | 15 | 17.0 |
*Immunity | 5 | 10.0 |
Nutrition Disorders/*immunology | 3 | 50.0 |
Chimeric Proteins | 2 | 2.0 |
Hybridomas | 2 | 1.0 |
Immunoglobulin Constant Region/*metabolism | 2 | 100.0 |
Immunoglobulins, Heavy-Chain/*metabolism | 2 | 50.0 |
Recombinant Proteins | 4 | 0.0 |
Complement Inactivators/metabolism | 3 | 15.0 |
Hypersensitivity, Immediate/*immunology | 2 | 7.0 |
Linear Models | 3 | 0.0 |
Antibodies, Antinuclear/metabolism | 3 | 60.0 |
Safety | 2 | 1.0 |
Alpha Rhythm | 2 | 13.0 |
Delta Rhythm | 2 | 16.0 |
Heart Rate/drug effects | 2 | 0.0 |
Complement Fixation Tests | 31 | 34.0 |
*Macrophage Activation | 3 | 5.0 |
Antibodies, Fungal/immunology | 2 | 33.0 |
Cryptococcus neoformans/*immunology | 3 | 15.0 |
Polysaccharides/*immunology | 2 | 28.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
*Haplotypes | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Transferrin/*genetics | 6 | 12.0 |
Lipopolysaccharides/*metabolism | 2 | 1.0 |
Neuraminidase/pharmacology | 6 | 8.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Sheep | 19 | 3.0 |
Complement 3 Convertase/analysis | 2 | 50.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Esters | 4 | 12.0 |
*Protein Conformation | 2 | 0.0 |
*Cardiac Surgical Procedures | 4 | 8.0 |
Complement/*immunology/metabolism | 3 | 50.0 |
Immunization | 8 | 2.0 |
Molecular Weight | 61 | 2.0 |
Serotyping | 8 | 3.0 |
Complement/*biosynthesis | 22 | 61.0 |
Indicators and Reagents | 2 | 0.0 |
*Immunotherapy | 2 | 1.0 |
Ultrafiltration | 2 | 3.0 |
Albumins/metabolism | 2 | 1.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
alpha 1-Antitrypsin/metabolism | 4 | 8.0 |
Complement 3/*deficiency | 12 | 92.0 |
Chromatography, Gel | 14 | 1.0 |
Hemolysis/immunology | 2 | 13.0 |
Lupus Erythematosus, Systemic/*metabolism | 2 | 13.0 |
Anticoagulants/*pharmacology | 3 | 3.0 |
Heparin/*pharmacology | 8 | 5.0 |
Signal Transduction | 3 | 0.0 |
Glomerulonephritis/*immunology | 19 | 50.0 |
Antibodies, Bacterial/immunology | 6 | 14.0 |
*Blood Bactericidal Activity | 5 | 10.0 |
Campylobacter fetus/immunology | 2 | 100.0 |
Complement 2/deficiency | 6 | 26.0 |
Complement Factor B/deficiency | 3 | 60.0 |
*Linkage (Genetics) | 10 | 0.0 |
Mice, Inbred C3H | 4 | 0.0 |
Biological Markers/*analysis | 2 | 1.0 |
Cytokines/analysis | 2 | 2.0 |
HIV Antibodies/analysis | 2 | 4.0 |
HIV Infections/*immunology | 4 | 0.0 |
Immunoglobulin A, Secretory/analysis | 3 | 16.0 |
Tissue Distribution | 9 | 0.0 |
Glomerulonephritis/*metabolism/pathology | 2 | 14.0 |
Kidney Glomerulus/*metabolism/pathology | 2 | 15.0 |
Complement 3b/analysis | 11 | 52.0 |
Antigens, Viral/metabolism | 2 | 9.0 |
Mice, Inbred A | 2 | 3.0 |
RNA, Viral/analysis | 2 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Half-Life | 4 | 0.0 |
Complement 3/*genetics/immunology | 2 | 100.0 |
Immunosuppression | 2 | 1.0 |
Lipopolysaccharides | 2 | 1.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
Turpentine | 2 | 50.0 |
Amputation | 2 | 14.0 |
Hypersensitivity, Delayed | 2 | 3.0 |
Immunoglobulin E/*analysis | 2 | 10.0 |
Skin/pathology | 7 | 2.0 |
Opsonins/metabolism | 3 | 12.0 |
Median Nerve/physiology | 2 | 11.0 |
Immunoglobulin G/*immunology | 7 | 7.0 |
*Antigens, Bacterial | 8 | 14.0 |
*Bacterial Outer Membrane Proteins | 4 | 25.0 |
*Carrier Proteins | 5 | 0.0 |
Streptococcus pyogenes/*immunology | 4 | 20.0 |
*Evoked Potentials, Visual | 2 | 7.0 |
Glomerular Mesangium/*immunology/metabolism | 2 | 100.0 |
Glomerulonephritis/immunology | 10 | 43.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Neoplasm Metastasis | 6 | 0.0 |
Event-Related Potentials, P300/physiology | 2 | 66.0 |
Pattern Recognition, Visual/*physiology | 2 | 9.0 |
Kidney Tubules/*immunology | 2 | 33.0 |
Hemorrhage/chemically induced | 2 | 12.0 |
Isoelectric Point | 5 | 4.0 |
Mice, Inbred Strains | 5 | 0.0 |
Italy | 8 | 1.0 |
*Quality of Life | 2 | 2.0 |
Blood Proteins/*physiology | 3 | 12.0 |
Glucose Tolerance Test | 3 | 0.0 |
Lipoproteins/blood | 2 | 0.0 |
Methods | 6 | 2.0 |
Neoplasm Staging | 8 | 0.0 |
*Gene Expression | 3 | 0.0 |
Glomerulonephritis, IGA/*genetics/metabolism/pathology | 2 | 100.0 |
Immunoglobulins/metabolism | 12 | 11.0 |
Antibodies, Viral/*immunology | 3 | 7.0 |
HIV Envelope Protein gp120/genetics/immunology | 2 | 13.0 |
Complement 3b/*analysis | 2 | 28.0 |
Complement Membrane Attack Complex/*analysis | 3 | 23.0 |
Epithelium/immunology | 4 | 2.0 |
Receptors, Fc/metabolism | 3 | 6.0 |
Infertility, Female/*immunology | 2 | 25.0 |
T-Lymphocytes/pathology | 2 | 1.0 |
Immunoglobulins/*blood | 6 | 18.0 |
Complement/*biosynthesis/genetics | 3 | 37.0 |
Cytokines/*pharmacology | 4 | 1.0 |
Epithelial Cells | 9 | 1.0 |
Glomerulonephritis/etiology/immunology | 3 | 75.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Leukemia, Promyelocytic, Acute | 2 | 3.0 |
Antigen-Antibody Complex/*analysis | 46 | 29.0 |
False Positive Reactions | 2 | 0.0 |
Immunoglobulins/*analysis | 37 | 37.0 |
Malaria, Falciparum/*immunology | 2 | 13.0 |
Antigen-Antibody Complex | 29 | 16.0 |
Complement/immunology | 11 | 11.0 |
Immunity | 2 | 3.0 |
T-Lymphocytes/immunology | 13 | 0.0 |
Evaluation Studies | 6 | 0.0 |
Histocytochemistry | 9 | 1.0 |
Interferon Type II/*pharmacology | 6 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 5 | 0.0 |
ABO Blood-Group System/genetics | 4 | 9.0 |
Genetic Markers | 8 | 0.0 |
Heterozygote Detection | 4 | 0.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
*Signal Processing, Computer-Assisted | 2 | 6.0 |
Antibodies/*immunology | 6 | 4.0 |
Complement/*analysis/immunology | 5 | 55.0 |
alpha 1-Antitrypsin/analysis | 12 | 13.0 |
Properdin/analysis | 14 | 77.0 |
Actins/metabolism | 2 | 0.0 |
Cell Movement/drug effects/physiology | 2 | 3.0 |
rhoA GTP-Binding Protein | 2 | 2.0 |
Interleukin-1/genetics | 2 | 2.0 |
Interleukin-6/genetics | 2 | 2.0 |
Glycosylation | 8 | 0.0 |
Major Histocompatibility Complex | 4 | 1.0 |
Staphylococcus aureus | 3 | 4.0 |
Blood Proteins/*genetics | 9 | 5.0 |
Models, Genetic | 2 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Complement 1 Inactivators/analysis | 2 | 22.0 |
Complement Pathway, Classical/drug effects | 6 | 26.0 |
Complement 4/*biosynthesis/genetics | 3 | 60.0 |
Muscle, Smooth, Vascular/immunology | 2 | 40.0 |
Complement 2/genetics | 4 | 8.0 |
Complement 4/genetics | 4 | 6.0 |
Ethnic Groups/*genetics | 3 | 1.0 |
Genetic Markers/genetics | 2 | 0.0 |
*Genetics, Population | 8 | 2.0 |
Heterozygote | 11 | 0.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
*Diet, Fat-Restricted | 2 | 10.0 |
Genes, abl | 2 | 5.0 |
Alzheimer Disease/immunology/*pathology | 3 | 50.0 |
Brain/pathology | 2 | 0.0 |
Inflammation/pathology | 2 | 3.0 |
Microglia/*physiology | 2 | 13.0 |
Complement 1/metabolism | 16 | 42.0 |
Complement Membrane Attack Complex/metabolism | 6 | 17.0 |
Autoimmunity/immunology | 2 | 6.0 |
DNA Primers/chemistry | 3 | 0.0 |
Complement 2/*genetics | 3 | 6.0 |
Complement 1s/biosynthesis | 2 | 66.0 |
Complement 2/biosynthesis | 11 | 68.0 |
Complement 4/biosynthesis | 7 | 43.0 |
Aorta, Abdominal/surgery | 2 | 28.0 |
*Blood Vessel Prosthesis | 2 | 6.0 |
Complement 1q/metabolism | 4 | 16.0 |
Complement 5a/metabolism | 2 | 14.0 |
Postoperative Complications/*immunology | 2 | 12.0 |
Complement Factor B/*genetics | 9 | 6.0 |
Antigen-Antibody Reactions/drug effects | 2 | 14.0 |
Glomerulonephritis, Membranoproliferative/*immunology | 6 | 66.0 |
Bone Marrow/pathology | 4 | 1.0 |
Gene Rearrangement | 2 | 0.0 |
Karyotyping | 6 | 0.0 |
Platelet Count | 13 | 2.0 |
Gene Library | 3 | 0.0 |
Properdin/metabolism | 9 | 60.0 |
Irrigation | 2 | 3.0 |
Antigen-Antibody Complex/*immunology/metabolism | 2 | 22.0 |
Complement 3b/*metabolism | 29 | 31.0 |
Inflammation/immunology | 3 | 2.0 |
Complement 5a/analysis | 2 | 40.0 |
Antigens, CD/*metabolism | 2 | 0.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Cell Aggregation | 3 | 2.0 |
Chickens | 3 | 0.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Adenosine Deaminase/genetics | 2 | 9.0 |
Glucosephosphate Dehydrogenase/genetics | 2 | 2.0 |
Autoimmune Diseases/blood/*immunology | 2 | 14.0 |
Liposomes | 4 | 1.0 |
Platelet Membrane Glycoproteins/*immunology | 2 | 6.0 |
Antibodies, Monoclonal/immunology | 19 | 1.0 |
HIV Antibodies/immunology | 2 | 3.0 |
Complement Pathway, Alternative/drug effects | 8 | 38.0 |
Intraoperative Period | 2 | 3.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 3 | 7.0 |
Peritonitis/etiology/*immunology | 2 | 28.0 |
Glomerulonephritis/etiology | 3 | 60.0 |
Kidney Diseases/*etiology | 2 | 20.0 |
Kidney Glomerulus/*pathology | 3 | 15.0 |
Adenosine Diphosphate Ribose/metabolism | 2 | 3.0 |
Platelet Membrane Glycoproteins/metabolism | 2 | 2.0 |
rho GTP-Binding Proteins | 2 | 7.0 |
Endopeptidases/metabolism | 3 | 2.0 |
Isoelectric Focusing | 12 | 2.0 |
Neoplasms/*immunology | 3 | 2.0 |
Neutrophils/*immunology | 9 | 5.0 |
*Phagocytosis | 17 | 14.0 |
Remission Induction | 4 | 0.0 |
Health Status | 2 | 2.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
*Interleukin-6 | 2 | 0.0 |
Antiviral Agents/*pharmacology | 2 | 1.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Streptococcal Infections/*complications | 5 | 38.0 |
*Lymphocyte Activation | 9 | 0.0 |
Linkage (Genetics) | 9 | 0.0 |
HLA Antigens/*analysis | 2 | 0.0 |
HLA-DR Antigens/analysis | 3 | 0.0 |
Complement 5/*immunology | 3 | 30.0 |
Endothelium, Vascular/immunology | 3 | 7.0 |
Myocardium/immunology | 2 | 18.0 |
Complement 5/*physiology | 3 | 50.0 |
Myocardium/*immunology | 2 | 11.0 |
Hypercholesterolemia/blood/*drug therapy | 2 | 8.0 |
Liver Function Tests | 2 | 1.0 |
Ultracentrifugation | 2 | 1.0 |
Combined Modality Therapy | 8 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
Complement Inactivators/pharmacology | 3 | 25.0 |
Citrates/pharmacology | 2 | 11.0 |
Protamines/pharmacology | 2 | 13.0 |
Complement 3a/analogs & derivatives/metabolism | 2 | 100.0 |
Phytohemagglutinins/pharmacology | 3 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 13 | 1.0 |
Complement 3/*analysis/immunology | 6 | 100.0 |
Arthritis, Rheumatoid/blood/immunology | 3 | 23.0 |
Lupus Erythematosus, Systemic/*blood/*immunology | 2 | 25.0 |
Complement 3/analysis/metabolism | 3 | 75.0 |
Anemia, Sickle Cell/*immunology | 3 | 50.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Antigen-Antibody Complex/metabolism | 9 | 16.0 |
Antigens, Surface/analysis | 4 | 0.0 |
Exons | 4 | 0.0 |
Precipitin Tests | 15 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Basement Membrane/immunology | 15 | 28.0 |
Glomerulonephritis/*immunology/metabolism/pathology | 2 | 66.0 |
Autoradiography | 10 | 1.0 |
Complement/*biosynthesis/isolation & purification | 2 | 66.0 |
Complement 3/biosynthesis | 13 | 48.0 |
Complement Factor B/biosynthesis | 11 | 64.0 |
Methionine/metabolism | 4 | 3.0 |
Sulfur Radioisotopes | 2 | 2.0 |
Point Mutation | 2 | 0.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Erythrocytes/*metabolism | 8 | 3.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Arthritis, Juvenile Rheumatoid/*immunology | 4 | 20.0 |
Immunoglobulin A/immunology | 6 | 16.0 |
Rheumatoid Factor/immunology | 5 | 38.0 |
Synovial Fluid/immunology | 5 | 13.0 |
Sensory Thresholds/physiology | 2 | 12.0 |
Peptide Mapping | 3 | 0.0 |
Candida/immunology | 2 | 16.0 |
Complement 6/biosynthesis | 3 | 75.0 |
Complement 7/biosynthesis | 2 | 100.0 |
Neutrophils/drug effects/*immunology | 2 | 6.0 |
Infusions, Intravenous | 4 | 0.0 |
Immunoglobulin M/*blood | 2 | 5.0 |
Opsonins/*blood | 2 | 100.0 |
Immunochemistry | 6 | 2.0 |
Substrate Specificity | 2 | 0.0 |
Myocardial Infarction/*immunology | 3 | 42.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*biosynthesis | 2 | 13.0 |
Goats | 2 | 2.0 |
Hemolysis/*physiology | 2 | 25.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Complement/deficiency | 6 | 60.0 |
Virus Replication | 2 | 0.0 |
*Plasma Exchange | 5 | 21.0 |
Antigens, CD19 | 2 | 1.0 |
Autoimmune Diseases/*immunology | 10 | 6.0 |
Bacterial Proteins/*immunology | 2 | 6.0 |
*Evolution | 3 | 1.0 |
alpha-Macroglobulins/*genetics | 2 | 4.0 |
*Complement 3/analysis | 4 | 100.0 |
Fetal Blood/*immunology | 2 | 2.0 |
*Immunoglobulin G/analysis | 2 | 50.0 |
Complement Hemolytic Activity Assay/methods | 2 | 66.0 |
HIV Antibodies/*immunology | 2 | 2.0 |
Endotoxins/pharmacology | 3 | 4.0 |
Immunoglobulin A/*immunology | 4 | 14.0 |
Monocytes/*drug effects/metabolism | 2 | 2.0 |
Fibronectins/*immunology | 2 | 66.0 |
Lactoferrin/analysis | 5 | 23.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Transplantation, Autologous | 3 | 0.0 |
Macaca mulatta | 3 | 0.0 |
*Carboxylesterase | 3 | 2.0 |
Poland | 3 | 2.0 |
Fibroblasts/immunology | 2 | 2.0 |
Epithelium/metabolism | 7 | 1.0 |
Graft Rejection/immunology/*pathology | 3 | 42.0 |
Heart Transplantation/immunology/*pathology | 2 | 22.0 |
Myocardium/*pathology | 2 | 5.0 |
*Blood Proteins | 4 | 5.0 |
Quality Control | 3 | 1.0 |
Creatinine/blood/urine | 2 | 9.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Hemolytic Plaque Technique | 9 | 15.0 |
Complement 1/analysis | 33 | 66.0 |
Complement 2/analysis | 13 | 44.0 |
Complement Inactivators/*analysis | 5 | 17.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Kidney Transplantation/immunology/*pathology | 2 | 66.0 |
Chemiluminescent Measurements | 4 | 2.0 |
Albumins/analysis | 4 | 10.0 |
Dialysis Solutions/analysis | 3 | 27.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 2 | 1.0 |
alpha-Macroglobulins/analysis | 5 | 12.0 |
DNA/chemistry | 2 | 0.0 |
Chromatography, Ion Exchange | 13 | 3.0 |
Chromosome Aberrations | 3 | 0.0 |
Complement 3/*deficiency/genetics | 12 | 100.0 |
RNA Splicing | 3 | 0.0 |
Hemorrhage/etiology | 3 | 14.0 |
Glycoproteins/*pharmacology | 3 | 3.0 |
Heparin/pharmacology | 3 | 1.0 |
Tumor Necrosis Factor-alpha/immunology | 2 | 1.0 |
Antigens, CD55 | 4 | 2.0 |
Arthritis/*immunology | 6 | 24.0 |
DNA/analysis | 6 | 0.0 |
Antibodies, Viral/immunology | 2 | 2.0 |
Cytomegalovirus/immunology | 2 | 2.0 |
Hepatitis C Antibodies | 2 | 16.0 |
Herpesvirus 4, Human/immunology | 4 | 5.0 |
Complement 3/physiology | 8 | 44.0 |
Thyroiditis, Autoimmune/immunology | 2 | 5.0 |
*Complement Hemolytic Activity Assay | 2 | 50.0 |
Methylprednisolone/administration & dosage | 2 | 10.0 |
Complement | 7 | 15.0 |
Erythrocyte Membrane/immunology | 4 | 10.0 |
Blood Proteins/analysis | 17 | 10.0 |
Liver Cirrhosis/*metabolism | 2 | 6.0 |
Proteins/*analysis | 4 | 2.0 |
*Cervical Vertebrae | 3 | 27.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Monocytes/immunology | 8 | 2.0 |
Complement 3/analysis/genetics | 2 | 66.0 |
Histocompatibility Testing | 5 | 0.0 |
Trypsin | 10 | 6.0 |
Receptors, Interleukin-2/*analysis | 2 | 2.0 |
Fibrinogen/*metabolism | 2 | 2.0 |
Thrombin Time | 2 | 9.0 |
Liver/cytology/*metabolism | 2 | 2.0 |
Blood Platelets/immunology | 3 | 4.0 |
Glomerulonephritis/*immunology/pathology | 9 | 60.0 |
Rats, Inbred Lew | 3 | 1.0 |
Bacterial Toxins/*toxicity | 3 | 14.0 |
Hela Cells | 2 | 0.0 |
Immunoglobulin G/*physiology | 3 | 33.0 |
Cholesterol/*blood | 2 | 0.0 |
Antibodies, Viral/analysis | 6 | 5.0 |
Antigen-Antibody Complex/analysis | 36 | 33.0 |
Antigens, Viral/analysis | 2 | 2.0 |
N-Acetylneuraminic Acid | 2 | 5.0 |
Neisseria gonorrhoeae/*immunology | 3 | 23.0 |
Larva/immunology | 3 | 42.0 |
Monocytes/*immunology | 15 | 3.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Capillaries/pathology | 2 | 4.0 |
Properdin/*analysis | 3 | 50.0 |
*Antigens, CD | 3 | 0.0 |
*Collectins | 6 | 37.0 |
Complement 3b Inactivators/immunology | 2 | 28.0 |
Scalp | 2 | 10.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Lung/cytology/*metabolism | 2 | 6.0 |
Complement Factor H/*biosynthesis/genetics | 2 | 100.0 |
Interleukin-2/pharmacology | 4 | 0.0 |
Antibodies, Bacterial/*analysis | 2 | 8.0 |
Mycobacterium leprae/*immunology | 3 | 10.0 |
Bone Marrow Cells | 2 | 0.0 |
Gels | 3 | 3.0 |
Immunoglobulins/biosynthesis | 2 | 1.0 |
Injections, Subcutaneous | 2 | 0.0 |
Peritoneal Cavity/cytology | 2 | 4.0 |
Random Allocation | 5 | 1.0 |
Arthritis, Rheumatoid/*immunology | 23 | 10.0 |
DNA Probes | 2 | 0.0 |
Osteoarthritis/*immunology | 2 | 18.0 |
Complement 3 Nephritic Factor/*analysis | 5 | 62.0 |
Streptococcal Infections/*immunology | 5 | 71.0 |
Receptors, Complement/*biosynthesis | 3 | 16.0 |
Protein Denaturation | 6 | 2.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
Carrier Proteins/immunology/metabolism | 2 | 15.0 |
Cell Membrane/immunology/metabolism | 3 | 2.0 |
Microscopy, Immunoelectron | 7 | 1.0 |
Cold | 3 | 2.0 |
Immunoglobulin G/*metabolism | 11 | 17.0 |
Apoptosis/drug effects | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Ascitic Fluid/immunology | 3 | 14.0 |
Peritonitis/prevention & control | 2 | 66.0 |
Antibodies/metabolism | 2 | 2.0 |
Bacterial Proteins/*analysis | 2 | 18.0 |
Plasma | 3 | 4.0 |
Receptors, Complement 3b/*metabolism | 2 | 10.0 |
Peptide Fragments/*analysis | 2 | 4.0 |
Chi-Square Distribution | 3 | 0.0 |
*Complement 3b | 3 | 37.0 |
Complement 4a/genetics | 2 | 10.0 |
Complement 4b/genetics | 2 | 9.0 |
Sweden | 2 | 0.0 |
Mesocricetus | 3 | 1.0 |
Complement 3 | 20 | 50.0 |
Liver Diseases/*blood | 2 | 6.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Vitronectin | 4 | 11.0 |
Zymosan/pharmacology | 10 | 11.0 |
Agglutination | 2 | 11.0 |
Cell Wall/immunology | 2 | 10.0 |
Immune Sera | 15 | 5.0 |
Antibodies | 7 | 1.0 |
Epithelium/physiology | 3 | 3.0 |
Complement 3b/*immunology | 7 | 29.0 |
Dinitrophenols/immunology | 4 | 66.0 |
Serum Albumin, Bovine/immunology | 5 | 20.0 |
AIDS-Related Complex/immunology | 2 | 5.0 |
Acquired Immunodeficiency Syndrome/*immunology | 3 | 1.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Complement 4/genetics/*metabolism | 2 | 50.0 |
Glomerulonephritis/immunology/*pathology | 4 | 57.0 |
Complement 3/biosynthesis/*genetics | 3 | 100.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Blood Proteins/isolation & purification/*metabolism | 2 | 22.0 |
Cations | 2 | 2.0 |
Leukocytes/*metabolism | 2 | 2.0 |
Amino Acids/analysis | 9 | 3.0 |
Glucocorticoids/*pharmacology | 3 | 1.0 |
Staining and Labeling | 5 | 0.0 |
*Complement Pathway, Alternative/drug effects | 4 | 80.0 |
Oxygen/blood | 2 | 1.0 |
Antithrombin III/metabolism | 3 | 2.0 |
Protease Inhibitors/*blood | 2 | 14.0 |
alpha-Macroglobulins/metabolism | 4 | 8.0 |
T-Lymphocytes/*immunology | 7 | 0.0 |
Oxygen Consumption | 5 | 2.0 |
Opsonins/*physiology | 3 | 37.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
Blood Group Antigens/*genetics | 3 | 2.0 |
Gene Frequency/genetics | 2 | 0.0 |
Lod Score | 6 | 0.0 |
Complement 3b Inactivators/pharmacology | 2 | 18.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Fluorouracil/therapeutic use | 2 | 4.0 |
Proteins/*genetics | 2 | 0.0 |
European Continental Ancestry Group | 4 | 0.0 |
Immune Complex Diseases/*immunology/pathology | 2 | 100.0 |
Clostridium botulinum/*enzymology | 2 | 100.0 |
Sodium Dodecyl Sulfate/*pharmacology | 2 | 28.0 |
Circular Dichroism | 7 | 1.0 |
Immune Sera/immunology | 4 | 2.0 |
Guanidines/*therapeutic use | 2 | 28.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
Antibodies, Protozoan/*blood | 2 | 16.0 |
Plasmodium falciparum/*immunology | 2 | 4.0 |
Erythrocyte Membrane/*immunology | 4 | 8.0 |
Immunoglobulin A/*analysis | 12 | 21.0 |
Complement 3c/analysis | 4 | 40.0 |
Escherichia coli | 3 | 0.0 |
Immunoelectrophoresis, Two-Dimensional | 31 | 25.0 |
Autoantibodies/*immunology | 7 | 2.0 |
Kidney Glomerulus/*immunology | 5 | 20.0 |
Lipodystrophy/*immunology | 3 | 100.0 |
Complement 3/*chemistry | 4 | 80.0 |
Heparin/*chemistry | 2 | 20.0 |
Brain/physiology | 5 | 7.0 |
Enzyme Tests | 2 | 2.0 |
Leukocyte Elastase | 2 | 4.0 |
Fibronectins/blood | 2 | 9.0 |
Neutrophils/*metabolism | 3 | 1.0 |
Opsonins/*analysis | 3 | 75.0 |
Liver Diseases/*immunology | 3 | 15.0 |
Interferon Type II/biosynthesis | 2 | 0.0 |
Alanine Transaminase/blood | 3 | 1.0 |
Anti-Inflammatory Agents/*therapeutic use | 2 | 5.0 |
Prednisolone/*therapeutic use | 3 | 13.0 |
*Epitopes | 2 | 1.0 |
Drug Interactions | 5 | 0.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Kidney Failure, Chronic/immunology/therapy | 2 | 20.0 |
Genes | 3 | 1.0 |
Complement 3d/*analysis | 3 | 50.0 |
Polyethylene Glycols | 5 | 5.0 |
Complement 5/biosynthesis | 7 | 70.0 |
Complement 8/biosynthesis | 3 | 100.0 |
Immunoglobulin M/physiology | 2 | 18.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Interferon-gamma, Recombinant/immunology | 2 | 33.0 |
Psoriasis/*immunology | 3 | 17.0 |
Immunoglobulin A/metabolism | 8 | 15.0 |
Immunoglobulin Isotypes/immunology | 2 | 6.0 |
Immunoglobulins/*immunology | 3 | 10.0 |
Polysaccharides, Bacterial | 2 | 28.0 |
Streptococcal Infections/immunology | 2 | 20.0 |
Interferon-gamma, Recombinant/*pharmacology | 3 | 2.0 |
*Oxygenators | 2 | 66.0 |
Streptococcus agalactiae/*pathogenicity | 2 | 100.0 |
Pregnancy/*immunology | 2 | 3.0 |
Thrombocytopenia/etiology | 2 | 7.0 |
Neutrophils/*physiology | 3 | 2.0 |
Complement 3 Convertase/immunology | 4 | 80.0 |
Fetus/*immunology | 2 | 4.0 |
Trophoblasts/immunology | 2 | 6.0 |
Antibodies, Anti-Idiotypic/immunology | 3 | 7.0 |
Autoantibodies/immunology | 4 | 3.0 |
Complement 3 Nephritic Factor/*immunology | 4 | 66.0 |
Meta-Analysis | 2 | 1.0 |
*Antibody Specificity | 2 | 2.0 |
Complement 4/*chemistry | 2 | 66.0 |
Esters/chemistry | 2 | 50.0 |
Glutamic Acid | 2 | 2.0 |
Sulfhydryl Compounds/chemistry | 2 | 11.0 |
Gene Expression/drug effects | 6 | 0.0 |
Amyloid/*metabolism | 3 | 5.0 |
Pregnancy Complications/*immunology | 3 | 23.0 |
Neutrophils/physiology | 3 | 2.0 |
Calcium/pharmacology | 3 | 1.0 |
Magnesium/pharmacology | 9 | 7.0 |
Protein Denaturation/drug effects | 2 | 15.0 |
Complement 3b Inactivators/*metabolism | 4 | 50.0 |
Complement Factor H | 39 | 51.0 |
Rats, Inbred Strains | 7 | 0.0 |
Complement 3/*physiology | 15 | 68.0 |
Macrophages/*immunology | 13 | 5.0 |
Antibodies/analysis | 6 | 4.0 |
Haemophilus Infections/*immunology | 2 | 66.0 |
Haemophilus influenzae/*immunology | 3 | 13.0 |
Opsonins | 9 | 21.0 |
Immunoglobulin M/*analysis | 7 | 15.0 |
Chromosome Deletion | 3 | 0.0 |
Introns | 2 | 0.0 |
Antibodies, Bacterial/analysis | 6 | 17.0 |
Cysteine | 3 | 2.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Lipopolysaccharides/immunology | 3 | 2.0 |
Immunodiffusion | 32 | 12.0 |
Complement 3d/analysis | 8 | 53.0 |
Complement Factor B/blood | 2 | 100.0 |
DNA/*genetics | 3 | 0.0 |
Bacterial Infections/*immunology | 3 | 9.0 |
Circadian Rhythm/*physiology | 2 | 2.0 |
Antibodies, Bacterial/*immunology | 6 | 24.0 |
Polysaccharides, Bacterial/*immunology | 2 | 8.0 |
Streptococcus pneumoniae/*immunology | 2 | 6.0 |
Carbohydrates/analysis | 2 | 3.0 |
Ceruloplasmin/analysis | 3 | 10.0 |
Granulocytes/enzymology | 2 | 16.0 |
Haptoglobins/analysis | 5 | 17.0 |
*Immunoglobulins | 3 | 10.0 |
Pseudomonas aeruginosa/*enzymology | 2 | 20.0 |
Serine Endopeptidases/*pharmacology | 2 | 20.0 |
Kidney Diseases/etiology | 2 | 11.0 |
Cellulose/analogs & derivatives | 3 | 10.0 |
Complement 3b Inactivators/physiology | 4 | 57.0 |
Complement Factor B/physiology | 5 | 45.0 |
Complement/*genetics/metabolism | 2 | 100.0 |
Integrin alphaXbeta2 | 6 | 16.0 |
Erythrocytes/metabolism | 7 | 3.0 |
Macrophage-1 Antigen/*metabolism | 2 | 10.0 |
Blood/*immunology | 2 | 15.0 |
Cell Adhesion | 8 | 0.0 |
Macrophages/*metabolism | 2 | 0.0 |
Opsonins/*metabolism | 2 | 33.0 |
Bacterial Outer Membrane Proteins/*immunology | 3 | 12.0 |
Complement 3 Convertase/*immunology | 4 | 80.0 |
Glomerulonephritis, Membranoproliferative/immunology | 2 | 33.0 |
Gastrectomy | 2 | 3.0 |
Complement 5/analysis | 25 | 56.0 |
Complement 6/metabolism | 2 | 20.0 |
Liver Cirrhosis, Biliary/*immunology | 5 | 14.0 |
Immunity, Natural | 3 | 1.0 |
*Splenectomy | 2 | 6.0 |
Complement 3b Inactivators/metabolism | 14 | 58.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
Lupus Erythematosus, Systemic/*diagnosis/immunology | 2 | 66.0 |
Complement 3/*analysis/genetics | 2 | 100.0 |
Erythrocytes/immunology | 24 | 9.0 |
Complement Factor D/*analysis | 2 | 100.0 |
Methylamines/pharmacology | 2 | 9.0 |
Receptors, Complement/physiology | 5 | 26.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Prednisolone/*administration & dosage | 2 | 16.0 |
Cyanogen Bromide | 2 | 3.0 |
Antigens | 3 | 3.0 |
Immunoglobulin G | 18 | 14.0 |
Antigens, Bacterial/*immunology | 3 | 2.0 |
Pseudomonas aeruginosa/*immunology | 4 | 36.0 |
Cryptococcus neoformans/*immunology/ultrastructure | 2 | 100.0 |
Membrane Proteins/*immunology | 2 | 3.0 |
Occipital Lobe/physiology | 3 | 30.0 |
Arthritis, Rheumatoid/genetics/*metabolism | 2 | 50.0 |
Glycoproteins/*genetics/metabolism | 2 | 5.0 |
Injections, Intra-Articular | 2 | 8.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Properdin/*metabolism | 9 | 90.0 |
Antibodies, Anti-Idiotypic/analysis | 3 | 11.0 |
Rheumatoid Factor/*analysis | 5 | 23.0 |
Interleukin-2/*pharmacology | 2 | 0.0 |
Blood Urea Nitrogen | 3 | 5.0 |
Fibrinogen/analysis | 10 | 5.0 |
Complement Factor D/*metabolism | 2 | 100.0 |
Edetic Acid | 10 | 24.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Immunoassay/methods | 4 | 7.0 |
Antigen-Antibody Complex/analysis/*immunology | 2 | 100.0 |
Antigens/analysis | 5 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 2 | 3.0 |
Receptors, Complement/metabolism | 6 | 10.0 |
Receptors, Complement 3d | 7 | 5.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
T-Lymphocytes, Helper-Inducer/metabolism | 2 | 12.0 |
Blood Grouping and Crossmatching | 2 | 2.0 |
*Chromosomes, Human, Pair 19 | 3 | 0.0 |
*Enzyme-Linked Immunosorbent Assay | 9 | 11.0 |
Graves' Disease/immunology | 2 | 4.0 |
Complement 9/biosynthesis | 2 | 100.0 |
Consanguinity | 2 | 0.0 |
Immune Adherence Reaction | 9 | 20.0 |
Receptors, Complement 3b | 31 | 9.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Regional Blood Flow | 3 | 2.0 |
Spectrophotometry, Ultraviolet | 3 | 1.0 |
Insulin/*therapeutic use | 2 | 2.0 |
Synovial Fluid/*immunology | 10 | 17.0 |
Dipeptides/*pharmacology | 2 | 11.0 |
Immunologic Techniques | 13 | 4.0 |
Estradiol/*pharmacology | 2 | 0.0 |
*Exons | 2 | 0.0 |
*Introns | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Complement 9/*analysis | 3 | 23.0 |
Rheumatoid Factor/analysis | 14 | 22.0 |
Complement 1/*metabolism | 2 | 7.0 |
*Antigen-Antibody Complex | 19 | 32.0 |
Capillaries/ultrastructure | 2 | 14.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Bronchi/pathology | 2 | 10.0 |
Complement 3/*biosynthesis/metabolism | 4 | 100.0 |
Monocytes/*immunology/metabolism | 2 | 5.0 |
Cobra Venoms/*pharmacology | 2 | 25.0 |
Complement Inactivators | 4 | 21.0 |
Cerebrospinal Fluid Proteins/analysis | 2 | 8.0 |
Serologic Tests | 2 | 2.0 |
Skin/immunology/pathology | 4 | 9.0 |
Epitopes | 11 | 1.0 |
Immunoglobulin M/*immunology | 4 | 6.0 |
Lymphocytes/immunology | 12 | 3.0 |
Area Under Curve | 2 | 0.0 |
Frontal Lobe/physiology | 2 | 25.0 |
Parietal Lobe/physiology | 2 | 33.0 |
Temporal Lobe/physiology | 2 | 33.0 |
Fetal Blood/immunology | 3 | 4.0 |
Reading | 2 | 16.0 |
Basement Membrane/metabolism | 2 | 3.0 |
Kidney Glomerulus/*metabolism/ultrastructure | 2 | 25.0 |
*Ethnic Groups | 3 | 2.0 |
Glomerular Mesangium/ultrastructure | 2 | 100.0 |
Hepatitis B/*complications | 3 | 20.0 |
Hepatitis B Antigens/analysis | 3 | 30.0 |
Organ Specificity | 2 | 0.0 |
*Immunoenzyme Techniques | 5 | 4.0 |
Kidney Glomerulus/immunology | 10 | 33.0 |
Complement Factor I | 6 | 28.0 |
Dexamethasone/pharmacology | 4 | 0.0 |
Glycoproteins/metabolism | 3 | 1.0 |
Properdin/*physiology | 2 | 100.0 |
Streptococcus pyogenes/immunology | 2 | 25.0 |
Cytokines | 2 | 1.0 |
Pulmonary Alveoli/cytology | 3 | 13.0 |
Complement 3/antagonists & inhibitors | 4 | 66.0 |
Complement 5/antagonists & inhibitors | 2 | 28.0 |
Necrosis | 2 | 0.0 |
*Lenses, Intraocular | 2 | 50.0 |
Hepatitis B Surface Antigens/analysis | 7 | 12.0 |
Hepatitis B e Antigens/analysis | 4 | 26.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Lichen Planus/*immunology | 3 | 37.0 |
Pemphigoid, Bullous/*immunology | 3 | 16.0 |
Skin Diseases, Vesiculobullous/*immunology | 7 | 31.0 |
*Bacterial Toxins | 2 | 1.0 |
*Superantigens | 2 | 4.0 |
Anti-Bacterial Agents/therapeutic use | 2 | 1.0 |
Glomerulonephritis/complications | 3 | 37.0 |
Arthritis, Rheumatoid/blood | 3 | 11.0 |
*Immunoelectrophoresis | 5 | 41.0 |
Steroids/therapeutic use | 2 | 5.0 |
Electrophoresis | 8 | 2.0 |
Crohn Disease/*immunology | 6 | 15.0 |
Buffers | 2 | 1.0 |
Complement 3/*biosynthesis/secretion | 2 | 66.0 |
Complement 3 Nephritic Factor/immunology | 2 | 100.0 |
Complement Activating Enzymes/*immunology | 6 | 66.0 |
Kidney/immunology | 5 | 12.0 |
Autoantibodies/*biosynthesis | 2 | 3.0 |
Vasculitis/*immunology | 2 | 10.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 4 | 4.0 |
Immunoglobulin Allotypes/*genetics | 6 | 27.0 |
Immunoglobulins/immunology | 7 | 15.0 |
Proteinuria | 4 | 10.0 |
Enzyme Precursors/*genetics | 2 | 1.0 |
Hungary | 2 | 3.0 |
Antibody-Dependent Cell Cytotoxicity | 3 | 3.0 |
Complement 1q/*metabolism | 2 | 10.0 |
Blood Transfusion/*adverse effects | 2 | 3.0 |
Fluoroimmunoassay | 2 | 4.0 |
Complement Factor D/physiology | 2 | 50.0 |
Lupus Nephritis/*drug therapy/immunology | 2 | 100.0 |
Enzyme Precursors/*analysis | 6 | 46.0 |
Fetal Blood/analysis | 3 | 5.0 |
Concanavalin A | 4 | 8.0 |
Peptide Fragments/isolation & purification | 2 | 3.0 |
Complement/*analysis/metabolism | 2 | 28.0 |
Fetal Blood/*analysis | 3 | 8.0 |
Gestational Age | 4 | 0.0 |
Complement 2/*deficiency/genetics | 2 | 7.0 |
Hepatitis B/*complications/immunology | 2 | 40.0 |
Hepatitis B Surface Antigens/*analysis | 5 | 17.0 |
Anaphylatoxins/analysis | 4 | 80.0 |
Diabetes Mellitus, Type 1/*immunology | 3 | 4.0 |
Arthritis, Rheumatoid/*immunology/pathology | 2 | 6.0 |
Meningitis, Meningococcal/*immunology | 2 | 33.0 |
Hypertension/etiology | 4 | 9.0 |
Receptors, Complement/*deficiency | 2 | 100.0 |
Luminescent Measurements | 3 | 3.0 |
Opsonins/immunology | 3 | 15.0 |
Staphylococcus aureus/*immunology | 3 | 3.0 |
Tunisia | 2 | 4.0 |
Macrophage-1 Antigen | 16 | 32.0 |
Streptococcus agalactiae/*immunology | 2 | 18.0 |
Cell Line, Tumor | 4 | 0.0 |
Antigens, Viral/*metabolism | 2 | 20.0 |
Complement 3/immunology/isolation & purification/*metabolism | 2 | 100.0 |
Coombs' Test | 5 | 17.0 |
Calcium | 3 | 10.0 |
Magnesium | 3 | 12.0 |
Methylamines | 3 | 33.0 |
Protease Inhibitors/pharmacology | 3 | 1.0 |
Sulfhydryl Compounds/analysis | 4 | 20.0 |
Complement 3/analysis/immunology | 3 | 75.0 |
Complement 4a | 5 | 8.0 |
Enzyme Precursors/*immunology | 2 | 22.0 |
Blood Coagulation Tests | 3 | 1.0 |
Blood Platelets/pathology | 2 | 11.0 |
*Hemostasis | 2 | 1.0 |
Disulfides | 3 | 3.0 |
Isoflurophate | 2 | 50.0 |
Neuraminidase/metabolism | 2 | 6.0 |
Diethylstilbestrol/pharmacology | 2 | 13.0 |
Complement Activating Enzymes | 2 | 14.0 |
Organ Culture Techniques | 2 | 0.0 |
Osteoarthritis/immunology | 2 | 10.0 |
Synovial Membrane/*immunology | 2 | 5.0 |
Asthma/*immunology | 4 | 4.0 |
Immunoglobulin E/analysis | 7 | 13.0 |
Nigeria | 5 | 8.0 |
Skin Tests | 7 | 3.0 |
Blood Donors | 5 | 2.0 |
Complement Factor D/analysis | 3 | 100.0 |
Multigene Family | 2 | 0.0 |
Complement 3/*isolation & purification/physiology | 2 | 100.0 |
Blood Coagulation Disorders/*etiology | 2 | 10.0 |
Blood Proteins/immunology | 2 | 10.0 |
Statistics | 2 | 0.0 |
Interleukin-1/physiology | 2 | 2.0 |
Liver/*metabolism | 2 | 0.0 |
Glycoproteins/blood | 2 | 3.0 |
Complement 3/*analysis/isolation & purification | 2 | 100.0 |
Cryptococcus/*immunology | 3 | 75.0 |
Properdin/physiology | 2 | 33.0 |
Infection/*immunology | 3 | 14.0 |
Purpura, Thrombocytopenic/*immunology | 4 | 40.0 |
Complement Factor B/genetics | 5 | 7.0 |
Interleukin-6 | 2 | 4.0 |
Receptors, Complement/*analysis | 8 | 10.0 |
Autoantigens/*immunology | 2 | 1.0 |
Dermatitis Herpetiformis/*immunology | 2 | 66.0 |
Lupus Erythematosus, Discoid/*immunology | 2 | 28.0 |
Blood Coagulation | 3 | 1.0 |
Fibrinolysis | 3 | 1.0 |
Hemorrhagic Fever, American/*blood/immunology | 2 | 100.0 |
Complement 3b/*physiology | 3 | 42.0 |
Peptide Fragments/*physiology | 2 | 7.0 |
Sepharose/metabolism | 2 | 11.0 |
Kidney/ultrastructure | 2 | 25.0 |
Complement 1q | 45 | 43.0 |
Complement 4/blood | 2 | 100.0 |
Lupus Erythematosus, Systemic/blood | 4 | 14.0 |
Erythrocytes/*physiology | 2 | 4.0 |
Complement 3d | 40 | 53.0 |
Arthritis, Rheumatoid/*metabolism | 2 | 3.0 |
Complement/biosynthesis/*metabolism | 2 | 66.0 |
Complement Membrane Attack Complex | 13 | 16.0 |
Pemphigus/*immunology | 3 | 7.0 |
Actuarial Analysis | 2 | 2.0 |
Plasmapheresis | 5 | 13.0 |
Chemotactic Factors/metabolism | 4 | 26.0 |
Complement 5a | 15 | 48.0 |
*Cytotoxicity, Immunologic | 3 | 0.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Complement 3/deficiency/metabolism | 3 | 100.0 |
Glomerulonephritis, Membranoproliferative/*blood/immunology | 2 | 100.0 |
Complement Fixation Tests/methods | 2 | 40.0 |
Electrophoresis, Polyacrylamide Gel/methods | 3 | 2.0 |
Lymphoid Tissue/*immunology | 2 | 7.0 |
*Genes, Structural | 2 | 0.0 |
Burns/*immunology | 2 | 14.0 |
Capillary Permeability | 2 | 2.0 |
Complement Activating Enzymes/metabolism | 11 | 40.0 |
Hydroxylamines/pharmacology | 2 | 22.0 |
*Complement Activation/drug effects | 3 | 20.0 |
Complement 3/*immunology/metabolism | 5 | 83.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Complement 1 Inactivators/*immunology | 2 | 66.0 |
Anti-Anxiety Agents/*pharmacology | 2 | 14.0 |
Diazepam/*pharmacology | 2 | 33.0 |
Blood Protein Electrophoresis | 11 | 10.0 |
*Postmortem Changes | 2 | 9.0 |
Colombia | 2 | 4.0 |
Plasma/*analysis | 2 | 25.0 |
Virus Diseases/immunology | 4 | 21.0 |
Complement Inactivators/*blood | 7 | 100.0 |
Kidney Glomerulus/analysis | 3 | 42.0 |
Cell Count | 4 | 0.0 |
Macrophages/immunology | 5 | 1.0 |
Opsonins/physiology | 3 | 75.0 |
Immunoglobulins, Heavy-Chain/*genetics | 2 | 1.0 |
Peptide Hydrolases/metabolism | 3 | 2.0 |
*Complement Fixation Tests | 4 | 57.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Protease Inhibitors | 3 | 17.0 |
Lasers | 2 | 1.0 |
Nephelometry and Turbidimetry | 6 | 8.0 |
Kidney Failure, Chronic/therapy | 2 | 5.0 |
Europe | 2 | 0.0 |
*Lasers | 2 | 9.0 |
Reference Standards | 4 | 1.0 |
Immunoglobulin G/physiology | 2 | 10.0 |
Complement 3b/immunology/*metabolism | 2 | 40.0 |
Solutions | 2 | 1.0 |
Complement 1/*analysis | 5 | 45.0 |
Complement 1 Inactivators/*analysis | 2 | 66.0 |
Complement Activating Enzymes/*analysis | 2 | 40.0 |
Complement 3a | 15 | 62.0 |
Properdin/*biosynthesis | 3 | 100.0 |
Blood Bactericidal Activity/drug effects | 2 | 20.0 |
Complement/deficiency/*metabolism | 2 | 66.0 |
Complement 3 Convertase/*blood | 2 | 100.0 |
Complement Activating Enzymes/*blood | 2 | 33.0 |
Antibodies, Antinuclear/immunology | 2 | 12.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 3 | 1.0 |
*Hemolysis | 11 | 12.0 |
Complement 3 Nephritic Factor/metabolism | 2 | 66.0 |
Blood Physiology | 4 | 5.0 |
*Coombs' Test | 2 | 20.0 |
Apolipoprotein A-I | 2 | 1.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Complement 5/*metabolism | 6 | 26.0 |
Enzyme Precursors/*metabolism | 5 | 4.0 |
Kidney Failure, Chronic/immunology | 3 | 60.0 |
Globins/*genetics | 2 | 1.0 |
Gorilla gorilla/genetics | 2 | 7.0 |
Chromatography, Agarose | 2 | 4.0 |
Complement 1 Inactivators/blood | 2 | 40.0 |
Complement 4b | 6 | 6.0 |
Haplorhini | 4 | 1.0 |
Lung Neoplasms/*immunology | 2 | 4.0 |
Complement 9/*metabolism | 2 | 5.0 |
Lupus Erythematosus, Systemic/*blood/immunology | 2 | 10.0 |
Immunoglobulins, Fc/analysis | 3 | 50.0 |
Receptors, Immunologic/analysis | 3 | 3.0 |
Complement 5/*analysis | 2 | 22.0 |
*Complement 3 | 24 | 82.0 |
Genes, Dominant | 4 | 0.0 |
HIV/*immunology | 2 | 1.0 |
HIV Antibodies | 3 | 5.0 |
Escherichia coli/*immunology | 2 | 5.0 |
Antibodies, Bacterial/physiology | 2 | 28.0 |
Glomerulonephritis/etiology/*immunology | 3 | 50.0 |
Neuraminidase | 2 | 5.0 |
Complement 3b Inactivators/*pharmacology | 3 | 100.0 |
Chondrocalcinosis/immunology | 2 | 100.0 |
Gout/immunology | 2 | 50.0 |
*Antigen-Antibody Reactions | 2 | 5.0 |
Vitamin D-Binding Protein/*genetics | 2 | 3.0 |
Complement/analysis/immunology | 3 | 50.0 |
Antibodies, Antinuclear/*analysis | 6 | 23.0 |
Complement 3/*analysis/metabolism | 5 | 83.0 |
Radioimmunoassay/methods | 2 | 1.0 |
Bacterial Infections/etiology | 2 | 25.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
DNA, Viral/*analysis | 2 | 2.0 |
Glomerulonephritis/*etiology/immunology | 3 | 100.0 |
Spinal Nerves/*immunology | 2 | 100.0 |
Fibronectins/*blood | 2 | 7.0 |
Glomerulonephritis, IGA/*immunology | 3 | 16.0 |
Enzymes/blood/*genetics | 2 | 33.0 |
Korea | 3 | 1.0 |
Mouth Diseases/*immunology | 2 | 25.0 |
Complement Activating Enzymes/analysis | 20 | 66.0 |
Histamine Release | 5 | 8.0 |
Leg | 2 | 4.0 |
Purpura/etiology | 2 | 50.0 |
Endocarditis, Bacterial/complications/*immunology | 2 | 100.0 |
Epitopes/immunology | 2 | 0.0 |
Complement 3c | 23 | 74.0 |
*Immunoelectrophoresis, Two-Dimensional | 2 | 50.0 |
Complement 3/analysis/*immunology | 3 | 50.0 |
Complement 3 Nephritic Factor/*blood | 5 | 100.0 |
Chemistry | 4 | 1.0 |
Methylamines/diagnostic use | 2 | 100.0 |
Complement 1r | 4 | 17.0 |
Complement 1s | 4 | 18.0 |
Complement Activating Enzymes/immunology | 3 | 30.0 |
T-Lymphocytes/analysis | 3 | 13.0 |
Chemotaxis, Leukocyte | 5 | 2.0 |
Dermatitis, Atopic/*immunology | 3 | 7.0 |
Neutrophils | 4 | 5.0 |
Glomerulonephritis/blood | 4 | 57.0 |
Immunoelectrophoresis, Two-Dimensional/methods | 3 | 50.0 |
Antigens, Surface/immunology | 2 | 1.0 |
Granulocytes/immunology | 3 | 5.0 |
Haptens | 4 | 33.0 |
Antigens, Bacterial/immunology | 3 | 2.0 |
HLA-B Antigens | 2 | 0.0 |
Chromatography, DEAE-Cellulose | 7 | 12.0 |
Agammaglobulinemia/immunology | 5 | 38.0 |
Polysaccharides, Bacterial/immunology | 2 | 15.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 3 | 1.0 |
Transferrin/analysis | 4 | 4.0 |
Calcium/physiology | 2 | 0.0 |
Recombination, Genetic | 7 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Complement 3b Inactivators/analysis | 4 | 80.0 |
Glomerulonephritis/etiology/*immunology/pathology | 3 | 75.0 |
Capillaries | 3 | 5.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Complement 3 Nephritic Factor/*metabolism | 2 | 100.0 |
Complement Activating Enzymes/*metabolism | 5 | 16.0 |
Complement Inactivators/*metabolism | 3 | 8.0 |
Lipodystrophy/immunology | 2 | 100.0 |
Enzyme Precursors/*biosynthesis | 3 | 27.0 |
Shock, Septic/*immunology | 2 | 14.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 2 | 4.0 |
Apolipoproteins/*genetics | 3 | 4.0 |
*Chromosomes, Human, 19-20 | 4 | 18.0 |
Mathematics | 3 | 1.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Melanoma/*immunology | 2 | 2.0 |
Models, Neurological | 2 | 1.0 |
Monocytes/*metabolism | 6 | 1.0 |
Indomethacin/pharmacology | 4 | 1.0 |
Monocytes/immunology/*metabolism | 3 | 6.0 |
Carrier Proteins/analysis | 3 | 3.0 |
Iodine Radioisotopes | 5 | 1.0 |
Polyethylene Glycols/diagnostic use | 3 | 37.0 |
Centrifugation, Density Gradient | 7 | 2.0 |
Lymph/*immunology | 2 | 40.0 |
Antigen-Antibody Complex/immunology/*isolation & purification | 2 | 50.0 |
*Immunosuppression | 2 | 2.0 |
Spleen/cytology | 2 | 1.0 |
Blood Group Antigens | 3 | 7.0 |
Myotonic Dystrophy/genetics | 2 | 14.0 |
O Antigens | 2 | 20.0 |
Complement 3/isolation & purification/*metabolism | 3 | 75.0 |
*Hemolysis/drug effects | 2 | 33.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Lymphocytes/*immunology | 5 | 1.0 |
Receptors, IgG | 4 | 2.0 |
Zymosan | 4 | 19.0 |
Complement Factor B/*analysis | 3 | 37.0 |
Liver | 2 | 3.0 |
HLA Antigens/*genetics | 4 | 0.0 |
Septicemia/immunology | 2 | 25.0 |
Complement 5a, des-Arginine | 2 | 28.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
Protein Precursors/metabolism | 2 | 1.0 |
Milk, Human/*immunology | 2 | 13.0 |
Muramidase/analysis | 2 | 7.0 |
Glomerular Filtration Rate | 2 | 1.0 |
Kidney Glomerulus/immunology/pathology/ultrastructure | 2 | 100.0 |
Nephrotic Syndrome/etiology | 3 | 100.0 |
Immunoglobulin M | 10 | 33.0 |
Immunoglobulin G/*genetics | 2 | 8.0 |
Hay Fever/immunology | 2 | 28.0 |
Hypersensitivity/*immunology | 2 | 4.0 |
Saliva/*immunology | 2 | 11.0 |
Urticaria/immunology | 2 | 50.0 |
Lupus Erythematosus, Systemic/complications/immunology | 3 | 75.0 |
Nephritis/etiology/immunology | 4 | 100.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 2 | 6.0 |
Latex Fixation Tests | 3 | 10.0 |
*Pregnancy | 7 | 5.0 |
*Chemotaxis, Leukocyte/drug effects | 2 | 14.0 |
Blood Platelets | 4 | 16.0 |
Complement Factor D/metabolism | 2 | 33.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Complement/*genetics/immunology | 2 | 100.0 |
Saccharomyces cerevisiae/immunology | 3 | 50.0 |
Sepharose/diagnostic use | 2 | 100.0 |
Lung/pathology | 2 | 2.0 |
Complement 5/deficiency | 2 | 20.0 |
Antibodies, Antinuclear/*immunology | 2 | 18.0 |
Methylmethacrylates | 2 | 18.0 |
Endopeptidases/pharmacology | 2 | 10.0 |
alpha 1-Antitrypsin | 2 | 20.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Macrophage Activation | 2 | 1.0 |
Neoplasms/immunology | 2 | 3.0 |
Purpura, Thrombocytopenic/immunology | 3 | 42.0 |
Thrombocytopenia/*immunology | 2 | 33.0 |
Immunoglobulin M/*metabolism | 2 | 5.0 |
Antigen-Antibody Complex/*isolation & purification | 3 | 37.0 |
Serum Albumin/immunology | 2 | 9.0 |
*Complement | 24 | 38.0 |
Complement 2 | 3 | 30.0 |
Complement 5 | 5 | 45.0 |
Complement Factor B | 3 | 25.0 |
Crystallization | 4 | 1.0 |
Antigens, Neoplasm | 2 | 5.0 |
Complement/biosynthesis | 3 | 42.0 |
Carcinoma, Bronchogenic/*immunology | 2 | 33.0 |
Pleural Effusion/*immunology | 2 | 20.0 |
*Occupational Exposure | 2 | 1.0 |
Kidney Glomerulus/pathology/ultrastructure | 3 | 60.0 |
Candida albicans/immunology | 3 | 6.0 |
*Phagocytosis/drug effects | 2 | 11.0 |
Trypan Blue/pharmacology | 2 | 12.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
Lymph Nodes/cytology | 2 | 4.0 |
Anilino Naphthalenesulfonates | 2 | 22.0 |
*Complement 3/immunology | 3 | 100.0 |
Spectrometry, Fluorescence | 4 | 0.0 |
Complement 3/analysis/*metabolism | 2 | 50.0 |
Otitis Media/*immunology | 3 | 100.0 |
*Antibody Formation/drug effects | 3 | 60.0 |
Pain Threshold/physiology | 2 | 40.0 |
Dengue/*immunology | 3 | 33.0 |
Rabbits/immunology | 10 | 10.0 |
*Complement 3b Inactivators | 2 | 50.0 |
Cell Membrane/ultrastructure | 2 | 4.0 |
Lupus Erythematosus, Systemic/*complications | 2 | 11.0 |
*Temperature | 2 | 6.0 |
Macrophages/*physiology | 2 | 2.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
*Plasmapheresis | 3 | 10.0 |
Histamine/blood | 2 | 11.0 |
Hypersensitivity, Delayed/immunology | 3 | 4.0 |
Immunoglobulin E/immunology | 3 | 5.0 |
Cystitis/*immunology | 2 | 100.0 |
Basement Membrane/immunology/pathology | 2 | 22.0 |
*Complement 4 | 2 | 25.0 |
*Immunoglobulin A/analysis | 2 | 40.0 |
Immune Complex Diseases/immunology | 5 | 50.0 |
Endopeptidases/*blood | 2 | 16.0 |
Granulocytes/*enzymology | 2 | 13.0 |
Neprilysin | 2 | 2.0 |
Basement Membrane/ultrastructure | 3 | 13.0 |
Neutrophils/*enzymology | 2 | 1.0 |
Immunoglobulins, Intravenous | 2 | 20.0 |
Radioligand Assay | 2 | 0.0 |
Infusions, Parenteral | 3 | 2.0 |
Antigen-Antibody Complex/*analysis/metabolism | 2 | 40.0 |
Serum Globulins/immunology | 2 | 50.0 |
Nephrotic Syndrome/*immunology | 2 | 25.0 |
Opsonins/analysis | 2 | 50.0 |
Lymphoma/immunology | 2 | 6.0 |
Lupus Erythematosus, Systemic/diagnosis/drug therapy/*immunology | 2 | 66.0 |
Lectins/*immunology | 2 | 7.0 |
Polyethylene Glycols/*diagnostic use | 2 | 40.0 |
Apolipoproteins E | 2 | 6.0 |
*Chromosome Mapping | 3 | 0.0 |
Colitis, Ulcerative/*immunology | 3 | 8.0 |
Dialysis | 2 | 4.0 |
Complement/*isolation & purification | 2 | 33.0 |
Complement 3 Convertase | 2 | 22.0 |
Nephritis/immunology | 5 | 55.0 |
Spain | 2 | 0.0 |
Glucose/*immunology | 2 | 100.0 |
Hemagglutinins/*immunology | 3 | 50.0 |
Isoantibodies/*analysis | 2 | 8.0 |
Contrast Media/*pharmacology | 3 | 50.0 |
Iodipamide/pharmacology | 2 | 100.0 |
Metrizamide/*pharmacology | 2 | 100.0 |
Thalassemia/blood/*genetics/physiopathology | 2 | 100.0 |
Complement 3/analysis/immunology/metabolism | 2 | 100.0 |
Complement 3b/*analysis/metabolism | 2 | 100.0 |
Complement Factor B/*analysis/metabolism | 2 | 100.0 |
Klebsiella pneumoniae/immunology | 4 | 66.0 |
Respiratory Distress Syndrome, Adult/immunology | 2 | 100.0 |
Bronchoalveolar Lavage Fluid/*enzymology | 2 | 50.0 |
Pneumonia/*etiology | 2 | 28.0 |
*Pulmonary Alveoli | 3 | 100.0 |
Hippocampus/immunology/pathology | 2 | 100.0 |
Neurofibrils/*ultrastructure | 2 | 50.0 |
Immune Complex Diseases/*etiology | 3 | 75.0 |
Bacteriolysis | 2 | 33.0 |
Leucine/metabolism | 3 | 4.0 |
Bacterial Infections/immunology | 2 | 8.0 |
Orosomucoid/analysis | 5 | 11.0 |
Glomerulonephritis/*genetics/immunology | 2 | 28.0 |
Anaphylaxis/*chemically induced | 2 | 100.0 |
Hemoglobinuria, Paroxysmal/*blood | 2 | 7.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Reiter Disease/immunology | 2 | 33.0 |
Spondylitis, Ankylosing/immunology | 2 | 15.0 |
Biological Assay | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Freezing | 3 | 3.0 |
Serum Globulins/metabolism | 3 | 30.0 |
Paraproteinemias/*immunology | 2 | 10.0 |
Complement Activating Enzymes/*biosynthesis | 3 | 42.0 |
Aspergillus fumigatus/immunology | 3 | 60.0 |
*Immune Tolerance | 2 | 1.0 |
Leprosy/*immunology | 2 | 8.0 |
Uric Acid/*pharmacology | 2 | 40.0 |
Magnesium/metabolism | 2 | 2.0 |
Complement 7/analysis | 5 | 45.0 |
Antibody Formation/*drug effects | 2 | 10.0 |
Antibody-Producing Cells/immunology | 2 | 8.0 |
Pokeweed Mitogens/pharmacology | 2 | 2.0 |
*Receptors, Complement | 3 | 25.0 |
Haploidy | 4 | 3.0 |
Receptors, Complement | 3 | 30.0 |
Counterimmunoelectrophoresis | 4 | 17.0 |
Leishmaniasis, Visceral/*immunology | 2 | 18.0 |
Vitamin D-Binding Protein | 2 | 7.0 |
Arthritis, Rheumatoid/complications/*immunology | 3 | 50.0 |
*Infant, Newborn | 3 | 6.0 |
Colostrum/*immunology | 2 | 25.0 |
Infant, Newborn, Diseases/*immunology | 2 | 66.0 |
Feedback | 2 | 1.0 |
*Lod Score | 2 | 5.0 |
*Immunoglobulin Allotypes | 3 | 37.0 |
*Immunoglobulin G | 3 | 17.0 |
Muramidase/immunology | 2 | 14.0 |
Cryoglobulins/analysis | 5 | 45.0 |
*Blood Coagulation | 2 | 0.0 |
Blood Coagulation Factors/analysis | 2 | 3.0 |
Feces/microbiology | 3 | 4.0 |
Protein Conformation/drug effects | 2 | 3.0 |
Sodium Dodecyl Sulfate | 3 | 5.0 |
Trypsin/pharmacology | 3 | 2.0 |
Immunoglobulins, Surface/analysis | 3 | 6.0 |
Membranes/immunology | 2 | 20.0 |
Vasculitis/*etiology | 3 | 30.0 |
Angioneurotic Edema/*diagnosis/genetics/immunology | 2 | 100.0 |
Erythrocytes/analysis | 2 | 8.0 |
*Chromosome Deletion | 2 | 0.0 |
Pseudomonas Infections/immunology | 2 | 40.0 |
Complement 3b Inactivators/*biosynthesis | 2 | 100.0 |
Glomerulonephritis/blood/*immunology | 2 | 40.0 |
*Antibodies | 2 | 4.0 |
Immunoglobulins, Fab | 2 | 3.0 |
Egtazic Acid | 2 | 25.0 |
Blood Proteins/biosynthesis | 3 | 14.0 |
Spondylitis, Ankylosing/*immunology | 2 | 13.0 |
alpha 1-Antitrypsin/*immunology | 2 | 100.0 |
Proteins/analysis | 2 | 1.0 |
Fetal Blood | 2 | 1.0 |
*Fluorescent Antibody Technique | 2 | 8.0 |
Skin Diseases/*immunology | 2 | 9.0 |
Immunoglobulin A, Secretory/*analysis | 2 | 15.0 |
*Serum Globulins | 2 | 66.0 |
Cystic Fibrosis/complications/*immunology | 2 | 40.0 |
Kidney Diseases/immunology | 3 | 42.0 |
Cornea/*immunology | 3 | 25.0 |
Complement 4 | 6 | 33.0 |
Immunoglobulin G/biosynthesis | 5 | 3.0 |
Immunoglobulin M/biosynthesis | 5 | 5.0 |
Venezuela | 2 | 6.0 |
*Antibody Formation | 4 | 4.0 |
Breast Neoplasms/immunology | 2 | 5.0 |
Kidney Diseases/*immunology | 3 | 25.0 |
Complement Activation/*radiation effects | 2 | 100.0 |
Complement 1 | 4 | 28.0 |
Stomatitis/immunology | 2 | 100.0 |
Macaca | 2 | 2.0 |
Complement 1/deficiency | 2 | 40.0 |
Antistreptolysin/analysis | 2 | 100.0 |
Lysosomes/enzymology | 2 | 3.0 |
Pancreatitis/*immunology | 2 | 18.0 |
Hemagglutination Tests | 5 | 5.0 |
Exudates and Transudates/immunology | 2 | 25.0 |
Bacteria/*immunology | 2 | 11.0 |
Complement 6/analysis | 5 | 38.0 |
Agglutination Tests | 2 | 4.0 |
Pneumococcal Infections/*immunology | 2 | 20.0 |
Obesity/*therapy | 2 | 40.0 |
Transplantation Immunology | 2 | 3.0 |
Albumins/cerebrospinal fluid | 2 | 33.0 |
Septicemia/*immunology | 3 | 42.0 |
Staphylococcal Infections/*immunology | 2 | 33.0 |
Multiple Myeloma/*immunology | 2 | 5.0 |
Waldenstrom Macroglobulinemia/immunology | 2 | 33.0 |
Cell Nucleus/immunology | 3 | 13.0 |
Skin/*immunology/pathology | 2 | 10.0 |
Germany, West | 2 | 4.0 |
*Immunity, Cellular | 3 | 2.0 |
Kidney/blood supply/pathology | 2 | 40.0 |
Complement 6 | 2 | 50.0 |
Complement 9 | 2 | 28.0 |
Blood Preservation | 2 | 2.0 |
Precipitins/analysis | 3 | 75.0 |
Immunodiffusion/methods | 2 | 11.0 |
Arterioles/pathology | 2 | 28.0 |
Carcinoma, Squamous Cell/immunology | 2 | 7.0 |
Amyloidosis/*etiology/immunology | 2 | 50.0 |
Immunoglobulins, lambda-Chain/analysis | 2 | 12.0 |
Anemia, Sickle Cell/immunology | 2 | 66.0 |
Rh-Hr Blood-Group System | 2 | 5.0 |
Hodgkin Disease/*immunology | 2 | 7.0 |
Lymphoma/*immunology | 2 | 6.0 |
*Immunoglobulins/analysis | 2 | 100.0 |
Immunoglobulin A | 5 | 55.0 |
Mexico | 2 | 2.0 |
Cytotoxicity Tests, Immunologic | 4 | 0.0 |
Hemolytic-Uremic Syndrome/*immunology/pathology | 2 | 100.0 |
Complement 8/analysis | 2 | 50.0 |
*Complement/analysis | 6 | 75.0 |
Antigens, Bacterial/analysis | 3 | 16.0 |
*Cryoglobulins | 2 | 40.0 |
*Counterimmunoelectrophoresis | 2 | 40.0 |
Eosinophils | 2 | 5.0 |
Epidermis/immunology | 2 | 9.0 |
Serum Albumin, Bovine | 3 | 12.0 |
*Genes | 2 | 0.0 |
*HLA Antigens | 3 | 1.0 |
*Histocompatibility Antigens | 3 | 4.0 |
Properdin | 2 | 33.0 |
Antibodies, Anti-Idiotypic | 4 | 19.0 |
*Autoantibodies/analysis | 2 | 66.0 |
*Immune Adherence Reaction | 3 | 42.0 |
Lymph Nodes/immunology | 2 | 2.0 |
Enzyme Precursors/metabolism | 2 | 1.0 |
Snake Venoms/pharmacology | 3 | 60.0 |
Gamma-Globulins/metabolism | 2 | 40.0 |
Continental Population Groups | 2 | 1.0 |
Kidney Glomerulus/immunology/ultrastructure | 2 | 50.0 |
Immunologic Deficiency Syndromes/*genetics/immunology | 2 | 13.0 |
*Alanine Transaminase | 2 | 66.0 |
Hyperlipidemia/*genetics | 2 | 9.0 |
*ABO Blood-Group System | 2 | 5.0 |
*Snake Venoms | 2 | 40.0 |
Polysaccharides | 2 | 33.0 |
Hematocrit | 3 | 0.0 |
Adenoids/immunology | 2 | 66.0 |
Dextrans | 2 | 4.0 |
Guinea Pigs/immunology | 3 | 20.0 |
Sheep/immunology | 5 | 20.0 |
Goats/immunology | 3 | 14.0 |
Cattle/immunology | 2 | 28.0 |
Aminocaproic Acids/*pharmacology | 2 | 66.0 |
Carrier Proteins/immunology | 2 | 5.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Cell Movement/*physiology | 2 | 0.0 |
rho GTP-Binding Proteins/antagonists & inhibitors/*metabolism | 2 | 22.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Protein Subunits | 2 | 0.0 |
